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ABSTRACT
l-/3-D-'Arabinofuran.osylcytosine (arabinosylcytosine, ara-C),
an analog of cytidine and deoxycytidine, kills organisms
ranging in complexity from viruses to mammals.
Clinically
it is effective in the chemotherapy of vaccinial infections
of the eye and actue leukemias. An increase in the therapeutic index of the drug will not only raise its effective¬
ness in the treatment of leukemias, but may also extend its
usefulness to the treatment of other neoplastic diseases.
A precise knowledge of the mechanism of action of the drug
might foster such a therapeutic advance by contributing to
the development arid use of improved treatment schedules.
Although the primary effect of the drug is an interfer¬
ence with the process of DNA synthesis, several different
mechanisms have been proposed to explain its lethal effect.
Because of the biochemical complexity of cells it is diffi¬
cult to establish the dominance of any one mechanism.
In
order to simplify the analysis, the drug1s effect on syn¬
chronously growing populations of cells was studied, and is
reported in this thesis.
Arabinosylcytosine at a relatively low concentration
(10"6 M) does not inhibit cell growth, if treatment is
limited to one hour. Deoxycytidine (ICT^ M) reverses the
effect of continuous treatment with the drug which lead to
cell death.
This agent also reduces the intracellular accumu¬
lation of the drug when given concomitantly with arabinosyl¬
cytosine.
Study of the drug's effect on synchronously grow¬
ing cells, shows that G1 cells are resistant to arabinosyl¬
cytosine at high concentrations (10"3 M).
On the other hand,
S cells are susceptible to treatment with ara-C at 10“^ M.
After exposure to the drug at this level, they could noc be
rescue d by deoxycytidine (10“^ M) even though the intracellu¬
lar concentration of the drug is significantly reduced after
drug treatment.
All cells killed by the drug underwent un¬
balanced growth, i.e. RNA and protein synthesis continued in
the absence of DNA synthesis.
Under certain conditions, this
process is reversible.
These observations confirm the findings of ethers and
explain deoxycytidine1s ability to reverse arabinosylcyto¬
sine ’s cytotoxicity.
They also reveal an immediate and irre¬
versible cytocidal effect of the drug on S cells.
A lethal
incorporation of the drug into DNA is consistant with and
best explains this effect.
Treatment of neoplastic diseases
with this drug would best be accomplished by intermittant high
dosage therapy.
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I.

A.

REVIEW OF THE LITERATURE

Chemistry of l~/3-D-Arabinofuranosylcytosine.
D-Arabinosyl nucleosides were first isolated

from a Carribbean sponge, Cryptothethya crypta (1,2).
Thymine was found to be the base component of the
first of two nucleosides to be purified (1).

The

sugar component was identified as D-arabinose (3).
The second D-Arabinosyl nucleoside, with uracil as
the base component, has also been described (3).
l.y5.»D-Arabinofuranosylcytosine (arabinosy Icy 'co¬
sine or ara-C) has not been found in nature, but is
the result of chemical synthesis.

Walwick et aI were

first to describe the synthesis of this compound by
phosphorylation of cytidine with polyphosphoric acid,
followed by enzymatic dephosphorylation of the nucleo¬
side diphosphate (4).

Commercial synthesis of the

drug, however, follows the procedure outlined by Hunter
in which D-arabinosyluracil is converted to arabinosy!cytosine via the thio derivative (3).

•>

.

'

-2-

B.

Inhibition of Viruses and Cells by Arabinosylcytosine.
The growth of several DNA viruses which infect

cell cultures are suppressed by arabinosylcytosine.
The replication of vaccinia (6), herpes simplex (7),
simian vacuolating virus 40 (8, 9), and adenovirus
12 (10) is prevented by the drug.

RNA viruses, cn the

other hand, such as influenza virus and Newcastle disease
virus, are not inhibited by arabinosylcytosine (7).
Viral infection of rabbit eyes by herpes simplex can
be cured by treatment with arabinosylcytosine solutions
(11,

12).

In human patients, topical arabinosylcytosine

has been used successfully to cure herpetic keratitis
(12,

13) and vaccinial blepharokeratitis (14).
Arabinosylcytosine has been reported to inhibit

the growth of JE. coli (15) and S. faecalis (16).

High

concentrations of the drug are required to inhibit
these organisms, as they rapidly dearoinate arabinosyl¬
cytosine to arabinosyluracil.

Arabinosyluracil has not

been reported to have growth inhibitory activity in bac¬
terial or mammalian cells.

Two strains of bacteria,

which are uracil auxotrophs, are in fact able to utilize

-3-

arabinosyluracil in place of uracil as a growth factor
(17).
Arabinosylc.ytosine is cytotoxic not only for a
number of established cell lines in culture, such as
L5178Y (18), LI210 (19), and KB (20), but also for
freshly explanted tissues, such as rat kidney cells
(7).

The drug extends the length of survival of ani¬

mals bearing transplanted tumors, including Sarcoma
180 (21), L1210 (21), L5178Y (22), Walker 256 (23),
Novikoff hepatoma (23), and C3H mammary tumors (24).
The standard treatment consists of 20 to 50 mg/kg of
drug administered daily for six days (25).

Arabino¬

sylcytosine has been tried as a therapeutic agent in
a number of human neoplastic diseases (26), but any
degree of success has been limited primarily to the
treatment of leukemias (27, 28, 29).

The drug's

chief adverse side effects have been bone marrow de¬
pression, megaloblastosis (26), nausea and vomiting
(30).

C.

Biochemistry cf Arabinosylcytosine.
1.

Effect on DMA synthesis. -- Arabinosylcytosine

inhibits DNA synthesis in viruses (31, 32) and cells

-4-

(33, 34, 35).

Treatment of infected cells during the

period of viral DNA replication inhibits the formation
of infectious virus particles (31, 32).

Addition of

the drug after viral DNA synthesis has been completed,
on the other hand, allows the formation of virus par¬
ticles (32).
The addition of arabinosylcytosine to cultures
prevents DNA synthesis in a number of cell lines.

It

has been shown that in short term leukocyte cultures,
few cells synthesizing DNA at the time of drug treat¬
ment reach metaphase (33).
the amount of

3

Drug treatment diminishes

H-deoxythymidine incorporated into the

DNA fraction of established cell lines, such as L929
(34), and KB (35), and short-term cultures of human
leukemic cells (36).

Ara-C (2 - 4 x 10”^ M) treated

L cells, substantially inhibited in their capacity to
incorporate thymidine-2-^C, however, regain their
ability to incorporate the radiochemical when resus¬
pended in drug free medium (37).
The synthesis of DNA by cell free extract of pri¬
mary rabbit kidney cells (38) and of Ehrlich ascite
cells (39) is inhibited in vitro by arabinosylcytosine.

5“

Using Ehrlich DNA polymerase, an inhibition of 70% is
„A

attained with arabinosylcytosine at 1,43 x 10

' M.

This inhibition can be completely reversed by the addi¬
tion of dCTP in the molar ratio of 2.86 to 1, ara-C to
dCTP (39).

Similar results were found in the rabbit

kidney preparations.

The inhibition of rabbit DNA poly

merase by ara-CMP (307, at 8.89 x 10"^ M) can be comPi etely reversed by dCTP in the molar ratio 6.62 to 1,
dCTP to ara-CMP (38).

Inhibition studies carried out

with a partially purified DNA polymerase isolated from
calf thymus shows competitive inhibition of the enzyme
with a Km for dCTP of 2.5 x 10"^ M, and a Ki for araCTP of 1.1 x 10“6 M (40).
Incorporation of arabinosylcytosine into nucleic
acids could not be demonstrated in partially purified
E.

coli DNA polymerase systems (41).

In a partially

purified mammalian enzyme system, ara-CTP does not sup¬
port DNA synthesis, when tested as a substrata in place
of dCTP (40).

In a similar system, ara-CTP is reported

to be incorporated at the 3 1 - hydroxyl terminal end
of the DMA molecule (41a).
ings has not been resolved.

This discrepancy in find¬
In whole cell studies, how

-6-

ever,

small amounts of ^H-ara-C have been found to be

incorporated into DNA
2.

(29,

34,

42).

Effect on RNA synthesis.

-- There appears to

be only a slight quantitative inhibition of RNA syn¬
thesis by arabinosylcytosine as measured by the incorporation of JH-uridine into the acid insoluble material
of whole cells

(47).

In a partially purified mammalian

enzyme system, ara-CTP does not support RNA polymeriza¬
tion when tested as a substrate in place of UTP (40).
Arabinosylcytosine does not inhibit the polymerization
of RNA by partially purified RNA polymerase systems iso¬
lated from E.

coli

(41) or calf thymus (40).

cell studies, however,

In whole

small amounts of ^R-ara-C have

been found to be incorporated into RNA (42).
Although overall RNA synthesis does not seem to be
inhibited,

the synthesis of a particular species of RNA

may be blocked by the drug.

In a study using He La cells,

the synthesis cf a 7 - 9s RNA which appears to be the
messenger RNA for group A histone polypetides is stopped
when these cells are treated with arabinosylcytosine
(44).

This inhibition does not appear to be specific¬

ally an arabinosylcytosine effect, however,

since similar

-7-

effects were observed after treatment with 5-fluorodeoxyuridine
3•

(45).

Entry °f Arabinosylc.ytosine into cells.

The ability of ara~C to inhibit cell multiplication
is linked to its ability to be accumulated by cells
(46,

47).

Although the uptake of arabinosylcytosine

appears to be mediated,

impairment of drug uptake in

resistant lines has not been found.
is rapid

Entry of the drug

(47) and appears to be similar to that des¬

cribed for other pyrimidine nucleosides

(48).

A de¬

crease in the intracellular accumulation of arabino¬
sylcytosine occurs when exogenous deoxycytidine is
provided along with the drug (29,
4.

49).

Phosphorylation of Arabinosylcytosine.

Ninety per cent of the ^K-arabinosylcytosine entering
the cellular acid soluble pool is converted to the diand tri-phosphate derivatives of the drug (47,

50).

Survival of tumor-bearing animals is directly correlated
with the ability of tumor cells to phosphorylate the
drug (46).
L1210 (V)

Ara-C resistant mutants of L5178Y (50),
(47),

and L1210 (46) have been found to be

deficient in their ability to phosphorylate %-ara-C or

-8-

deoxycytidine.

The kinase isolated from the L5178Y

mutant shows only 57% activity when compared to enzyme
preparations from arabinosylcytosine sensitive cells.
In metabolite-antimetabolite phosphorylation studies
with partially purified preparations of calf thymus
deoxyeytidine kinase,

arabinosylcytosine was found to

be a competitive inhibitor of dCyd

(Ki,

3.6 x 10“-

M),

and dCyd was found to be a potent competitive inhibitor
of ara-C (Ki,
5.

1.3 x 10"9 H)

(51).

Effect of Arabinosylcytosine on the Reduction
of Cytosine Monophosphate.

whole cells,

-- Treatment of

L5178Y, with arabinosylcytosine at 1.2 x

£
10" D M diminishes by 66% their ability to synthesize
dCMP from uridine (18).
is unaffected.

Formation of CMP from uridine

The pool size of dCyd phosphates in

arabinosylcytosine treated cells, however,
cient to support DNA synthesis

(52).

is suffi¬

Cell free ex¬

tracts of Ehrlich cells treated with arabinosylcytosine
-5
at 5 x 10*
M show a 35% decrease in their capacity to
reduce CDP to dCDP (53).

On the other hand,

a partially

purified reductase enzyme prepared from Novikcff as¬
cites tumor cells is only slightly inhibited by ara-

-9-

CTP.
2 x

Inhibition is 50% at a drug concentration of
10”3

m.

The enzyme system is not inhibited by

ara-C (54).
When the ability of primary rabbit kidney cells
to phosphorylate and reduce ^Ii-Cyd to ^H-dCMP in the
presence of arabinosyIcytosine was studied,

the acid

soluble pool of derived ®H~dCMP was the same as that
of the controls.
however,

The total amount of ^H-Cyd reduced,

is diminished by 80% in cells incubated with

arabiuosyleytosine at 1.78 x I0"6 M.

Incorporation

of ^H-dCMP into DNA was decreased by 96% (49).
bation of the rabbit kidney cells with dCyd
10”® M) and ara-C (3.56 x 10"? M)

Incu¬

(1.78 x

causes a 577, reduc-

tion in the amount of acid soluble -R-dCMP derived
from ^H-CR as compared to controls.
6.

Unbalanced Growth and Protein Synthesis.

--

When microorganisms which require thymine for growth
are grown in thymine-free medium,

a form of growth

characterized as unbalanced growth occurs

(55).

Con-

commitant with the culture's increasing turbidity as
the bacteria enlarge in size is a decrease in viability.

I

.

-10

RNA and protein synthesis appear to be normal, but no
DNA is synthesized.

Thymineless death appears to in¬

volve two distinct steps,

the first of which involves

RNA and protein synthesis during thymine starvation,
and the second of which requires continued thymine
starvation but is independent of RNA and protein syn¬
thesis (56).

In these microorganisms there is support

for the hypothesis that: thymineless death is caused by
the induction of a defective prophage (57, 53, 59).
Arabinosylcytosine induces a similar form of growth in
thymine less auxotrophs of several bacterial species
even when they are provided with up to fifty times the
usual amounts of thymine required for normal growth (60).
A phenomenon similar to thymineless 'death in bac¬
teria has been described in mammalian cells in which RNA
synthesis has been stopped by metabolic inhibitors such
as amethopterin (61) 5-fluorodeoxyuridine (62, 63),
high concentrations of thymidine (greater than 10~^ M)
(64, 65), hydroxyurea (66), or arabinosylcytosine (67,
68).

As with bacteria, RNA and protein accumulate in

these cells as they increase to two to three times their
usual volume.

Viability diminishes with time.

This

11-
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form of cell killing has been called thymidineless
death.

As with thymineless death,

tein synthesis

(by cycloheximide)

inhibition of pro¬
in these cells,

appears to reverse the lethal effects of the inhibi¬
tion of DNA synthesis

(69).

Unbalanced growth per se does not appear to be
lethal for a finite time.
synchronization (FUdR, MTX,

Several methods of cell
thymidine) depend on the

accumulation and collection of inhibited cells which
are simultaneously released from their blockage.
balanced growth in random cultures is,

Un¬

in fact, not

present until age distribution can no longer account
for an observed increase in any one rnacromolecuiar
component

(70).

Analysis of the functional capacity of the RNA
and protein synthesized has been limited.

In cells

undergoing unbalanced growth induced by 5-fluorodeoxyuridine, DNA polymerase is stable

(71).

This enzyme

is present and active in vitro in cells committed to
DNA synthesis even when DNA synthesis does not begin
(72,

73).

cells,

In a study using He La and Green monkey kidney

the activity of the enzyme deoxythymidine kinase

12-

-

increased in arabinosylcytosine treated cells

(68).

This might have been due to a partial synchrony of
the cell population.

Inhibition of the increase in

enzyme activity by cycloheximide, however,

suggests

that the increase in activity is the result of newly
synthesized enzyme.
seven fold)

There is an increase

(five to

in deoxynuclease activity in HeLa cells

undergoing unbalanced growth.

This increase in en¬

zyme activity appears to be a consequence of unbal¬
anced growth (74),

and is reversed when the cells

are allowed to recover (65).
Certain enzymes,

such as thymidine kinase and

deoxycytidine deaminase,

are apparently directly re¬

lated to virus replication and are induced in cells
infected with SV40 (8).

Although arabinosylcytosine

prevents the replication of the virus,

it does not in¬

hibit the synthesis of these biologically active pro¬
teins

(8,

75).

Related to SV 40 infection of cells

is the appearance of the nTM (tumor) antigen in the
nucleus of the host.
a virus induced enzyme

This antigen is thought to be
(76).

Arabinosylcytosine does

not inhibit the appearance of this antigen although it
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suppresses viral growth (9).

A similar situation is

found in Adenovirus 12 infections.

Arabinosylcytosine

inhibits the formation of virus particles but does not
inhibit the expression of the T antigen in infected
cells

(13).
7•

Reversal of Arabinosylcytosine Toxicity by

Deoxycy11dine.

It has been shown that deoxycytidine

will reverse the inhibition of growth of vaccinia virus
(6) and Moloney sarcoma virus
sylcytosine.

(77) caused by arabino¬

Animals bearing transplanted tumors,

as Ehrlich (78) and L1210 (19),

such

die at approximately the

same time as untreated tumor-bearing animals when deoxy¬
cy tidine is given along with arabinosylcytosine.

The

suppression of marrow regeneration in lethally irradiated
mice caused by arabinosylcytosine can be completely re¬
versed by giving deoxycytidine simultaneously with,
subsequent to drug treatment (79).

or

The cytotoxicity

induced by the drug in L5178Y and KeLa cells

(18,

67),

and the chromosomal aberrations associated with drug
treatment (80,

81) are both reduced by the presence of

deoxycytidine in the medium during or after arabinosyl¬
cytosine treatment.

Studies of a mutant

(car) of L5178Y
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indicate that its resistance to arabinosylcytosine is
due to its larger pool size of deoxycytidine nucleo¬
tides (82).

D.

Effect of Arabinosylcytosine on Chromosomes.

Chromosomal aberrations in arabinosylcytosine
treated cells have been reported by several investi¬
gators

(80,

81,

83).

The drug apparently induces a

variety of aberrations including terminal deletions,
interstitial deletions,

ring and dicentric chromosomes.

Although sufficiently high concentrations of arabino¬
sylcytosine stop DNA synthesis and would thereby appar¬
ently limit the drug’s effect to cells in G2

(SO),

it

appears that chromosomal aberrations can be induced in
all stages of the cell cycle

E,

(81).

The Cell Cycle.

Early in their study of cells,

microscopists recog¬

nized two phases of cell growth and development - mito¬
sis

(M) and interphase.

It was not until radioactive

DNA precursors became available, however,

that inter¬

phase could be subdivided into distinct periods now
called Gl,

S,

and G2 (84,

85,

86).

The cell cycle is
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a

progression of events between two consecutive mitoses.
Study of cellular processes during the cell cycle

has only recently been undertaken.

The synthesis and

activity of many cellular proteins,

organelles and sub-

cellular particles appear to be regulated and related
to a specific segment of the cell cycle.
replication,
manner,

for example,

Centriolar

takes place in a progressive

and discretely observable events such as ortho-

ganol centriolar separation and replication by budding
are temporally related to specific cell cycle periods
(?>7).
The rate of RNA synthesis is not constant, but
doubles during the first half of S

(88,

89,

90);

each

RNA species apparently undergoes a two fold increase in
rate

(90,

91).

Certain RNA species such as messenger

RNA and its resulting proteins may be synthesized only
during one specific portion of the cell cycle
DM,
tion,

(45,

46).

more critically related to cellular reproduc¬

may be replicated early in S.

The degree of

lethality (as measured by cloning efficiency)

of 5-bromo-

deoxyuridine when incorporated into DNA varies markedly
depending on whether the drug is incorporated into early
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(207o cloning efficiency)

or late

(70% cloning effi-

ciency) replicating DNA (92).
The activity of several enzymes appears to follow
characteristic patterns.

Thymidine kinase activity is

high in M, but drops as soon as the cells complete
division.

As the cells enter S,

the activity increases

until the cells begin their next division (93).

A block¬

ing of DNA synthesis does not prevent the reappearance
of the enzyme.

Enzyme activity appears to be related

to the size of the thymidylate pool rather than DNA syn¬
thesis per se:.
DNA polymerase activity parallels DNA synthesis
(94).

It is low in G1 cells,

just before S,

appears in the cytoplasm

and in both nuclei and cytoplasm in all

subsequent stages of the cell cycle

(95).

The activity

of thymidine phosphokina.se also closely parallels the
synthesis of DNA (96).
varies,

Thymidylate synthetase activity

peaking in mid-S and G2

(97).

Glucose-6-phos¬

phate and lactate dehydrogenase activity fluctuate dur¬
ing the cell cycle with peaks of activity in late Gl,
mid-S,

and early G2 (98).
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F.

Cell Synchronization.

Mammalian cell lines in culture have been syn¬
chronized in a number of ways.

Drugs such as Colcemid

(99) and Vinblastine (100), which arrest mitosis, have
been used to collect populations of cells which divide
synchronously after the drug is removed.
of thymidine (64,

High levels

101) and 5-fluorodeoxyuridine

(62,

102), which inhibit DNA synthesis, have been used to
collect populations of cells about to enter the S phase
of the cell cycle.

Because these latter agents have a

significant effect on the size of the pools of meta¬
bolites which directly participate in DNA synthesis,
interpretation of the effects of a second metabolic
inhibitor of DNA synthesis is difficult.
Since there is a relationship between cell size
and the stage of the cell cycle that a cell is in (103),
homogeneous populations of cells in a particular stage
of the cell cycle have been recovered by differential
centrifugation of cell suspensions

(104).

Cells which grow on a glass substrate are loosely
attached during mitosis, and a relatively minor disturb¬
ance as such as that produced by agitation of the cul-

ture medium will detach them (105).
then be collected by centrifugation.

These cells can
Because only a

small percentage of cells of a logarithmically grow¬
ing culture is in mitosis at any one time,
low.

yields are

Yields can be increased by first collecting cells

in mitosis by use of the antimitotic drug Colcemid
(106).

This drug,

a derivative of Colchicine,

is re¬

versibly bound to a protein subunit of microtubles
which are part of the mitotic apparatus

(107,

10S,

109).

These observations are the basis of the technique used
in these experiments (110).

G.

The Chemotherapy of Neoplastic Diseases.

Arabinosylcytosine, when given to human patients
as a single intravenous dose,
in an hour,
tected.

is rapidly cleared, with¬

from the blood to levels which cannot be de¬

Almost all (907o)

ated to arabinocyluridine,
creted by the kidneys

of the injected drug is dearainthe form in which it is ex¬

(111).

The capacity of the liver

to deaminate the drug is sufficient to account for its
observed catabolism (112).
Neoplastic cells as compared to normal cells may
have uniquely different series of cellular processes.
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The synthesis of nuclear proteins by He La cells,
example,

for

takes place throughout its cell cycle whereas

in normal cells synthesis is restricted to S

(113,

114).

This finding may not extend to all neoplastic cells,
since some HeLa cells do synthesize nuclear proteins
only during S

(45).

Analysis of the effects of chemotherapeutic agents
on host survival in transplanted tumor systems
116),

(115,

and on the ability of normal hematopoietic and

lymphoma cells to form splenic colonies

(117)

indicates

that these drugs, because of their relation to certain
defined cellular events,

act specifically and consist-

antly throughout or during a part of the cell cycle

(118).

It is believed that the therapeutic advantage of these
drugs with regard to extending host survival can be in¬
creased by a judicious scheduling of treatment.
The study of a drug's effect on synchronized cell
populations gives direct information about the agent's
cytotoxicity during the cell cycle and provides a sys¬
tem in which the mechanisms by which the toxicity occurs
can be investigated.

Such a study of arabinosylcytosine

is the subject of this thesis.
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II.

MATERIALS AND METHODS

A.

Materials.

1.

Cell culture medium.

-- All components of the

cell culture medium were purchased from Grand Island
Biological Company (Grand Island, New York).
bovine serum,

antibiotics,

frozen at -20°C.

Fetal

and 1-glutamine were stored

Complete culture medium consisted of

Eagle’s Minimal Essential Medium,

Earle’s salts,

supple¬

mented with 17% fetal bovine serum and nonessential
amino acids as recommended by Eagle

(119).

The medium

was purchased as a liquid concentrate and diluted with
sterile double glass distilled water containing sodium
bicarbonate.

In cultures with few cells there was some

difficulty maintaining a satisfactory pH of 7.2,

there¬

fore the amount of sodium bicarbonate was reduced by
ten percent from the original formulation of Earle
to two grams per liter of medium.

Before use,

(120)

1-gluta¬

mine was added to the medium at a final concentration
of 2 mM,
50 y^g/ml.

penicillin at 50 units/ml,

and streptomycin at
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2.

Trypsin solutions.

-- Cell monolayers were

detached from glass or plastic substrates by means of
either of two preparations containing trypsin.
talline trypsin (Worthington; Freehold,

New Jersey)

was used at a final concentration of 0.17o.
(VioBin; Monticello,

Illinois),

Crys¬

Vioc.ase

an uncharacterized

porcine pancreatic powder which contains a number of
hydrolytic enzymes including peptide hydrolases,
cerol ester hydrolases,

gly¬

and amylase, was used at a

final concentration of 0.25%.

A 2.5% (w/v)

solution

of viocase was prepared by stirring a 0.85% saline sus¬
pension of the powder for thirty minutes at 4°C.

After

removal of the insoluble residue by centrifugation for
thirty minutes at 10,000 x g,

the supernatant was steri¬

lized by filtration through a 0.45 micron membrane fil¬
ter (Millipore;

Bedford, Massachusetts).

The concentra¬

tion of the various enzymes in the final solution is un¬
known .
Final dilutions of both trypsin solutions were made
in Eagle's Minimal Essential Medium modified for spinner
cultures

(119).

To this basic formulation was added py¬

ruvic acid at a final concentration of 1 mM,

and nonessen
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tial amino acids.

All enzyme solutions were stored

frozen at -20°C.
3.

Drugs. -- Colcemid was purchased from the CIBA

Pharmaceutical Company (Summit, New Jersey).

Arabino-

sylcytosine was obtained from Dr. J. H. Hunter of the
Upjohn Chemical Company (Kalamazoo, Michigan).

Tri¬

tium labelled arabinosylcytosine was purchased from
Schwarz BioResearch.

Preparations of the isotopically

labelled drug which were less than 96% pure, as deter¬
mined by paper chromatography, were repurified.
4.

Radiochemicals. -- Radioactive

compounds were

purchased from Schwarz BioResearch (Orangeburg, New York).
O

These were deoxythymidine-methyl- II, 3c/mmole; uridine5-^H, 8c/mmole;

1-leucine-4, 5-^H,

6c/mmole; ^H-deoxycyti-

O

dine, 5c/mmole; and °H-cytidine,
5.

6c/mmole.

Biochemicals. -- Thymidine, deoxycytidine, deoxy-

adenosine, cytidine, deoxyguanosine, cytidine, adenosine,
and guanosine were purchased from Schwarz BioResearch.
6.

Culture vessels. -- Cells were routinely cul¬

tured in 16 oz. medicine bottles (Armstrong; Millville,
New Jersey).

Before use, these

were rinsed with demin¬

eralized water and sterilized at 170°C for six hours.

23-

-

When appropriate,
bottles

one ounce and three ounce medicine

(Armstrong) were used.

For convenience, because of the large numbers of
cells required,

subcultures made just before synchroni¬

zation experiments were done with 250 ml plastic flasks
(Falcon;

Los Angeles,

the synchronized

California).

In many experiments

population of cells was divided and

cultured in 30 ml plastic flasks

(Falcon).

The 16 x 125 mm disposable glass culture tubes
(Bellco; Vineland, New Jersey) used in cloning experi¬
ments were closed with no.
The 16 oz.
pers.

1 silicone rubber stoppers.

medicine bottles were closed with no.

5 stop¬

Silicone rubber stoppers were purchased from Mac-

alaster-Bicknell Company (New Haven,
7.

Preparation of glassware.

cleaned by soaking in a 1.35% (w/v)

Connecticut).

-- Pipettes were
sodium dichromate-

sulfuric acid solution, and in 0.25 N sodium hydroxide,
followed by thorough rinsings in distilled water.

Pip¬

ettes were cotton plugged and sterilized by dry heat in
stainless steel cans

(Ellisco; Philadelphia,

Pennsylvania).

Other glassware was cleaned in Haemo-sol (Meinecke; Union,
New Jersey)

and sterilized by dry heat when practical,

or
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by autoclaving.
8.

Cell counting.

-- Cell number and volume were

determined by use of a Coulter Electronic Cell Counter
(Hialeah, Florida),
plotter. Model K.
crons.

Model B, with a size distribution
The aperature tube pore was 100 mi¬

Cell samples were diluted in 0.9% saline.

Mean

cell volume was estimated by selecting the highest peak
in a size distribution plot of the cell population and
multiplying its value by the appropriate conversion
factor as determined by calibration of the instrument
with latex particles of known volume.
9.

Salt solution.

-- Drug and biochemical solu¬

tions were made at higher concentrations than used dur¬
ing an incubation.

Dilution of the concentrated solu¬

tions was made in Hanks’s Balanced Salt Solution (121,
Grand Island Biological Company) before addition to
cell cultures.

Hanks's solution was also used whenever

a serum free medium was required.
Liquid scintillation counting.

-*• All scintilla¬

tion counting was done in a Nuclear Chicago Mark I
tillation counter.
II

scin¬

Samples were put into Spectravials

(Nuclear Chicago; Des Plaines, Illinois).

The liquid
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scintillation counting solution consisted of a mixture
of 33% (v/v) ethanol in toluene containing 4.2 gm/1 of
2,5-Diphenyloxazole and 52.5 mg/1 of p-Bis £2-(5-phertylxazolyli/ -benzene.

The fluors were purchased as a

concentrated solution (Liquifluor,

New England Nuclear;

Boston, Massachusetts).
11.

Cell line.

The cell line used in these

studies was established by T.

C.

Hsu in September,

at the M. D. Anderson Hospital (Houstin, Texas),

1962,

from

the lungs of a male Chinese hamster (Cricetulus griseus),
Don.

It had been maintained in continuous culture in

the laboratory of origin in McCoy's 5a medium (122).
The "C" clone of the parent Don line was brought to
Yale

(Dr. Frank H,

Ruddle, Department of Biology)

in

1966 and grown in Eagle's Minimal Essential Medium
supplemented with 10% (v/v)
0.5% (w/v)

fetal bovine serum, and

lactalbumin hydrolysate.

cell was obtained in January,

1967,

An innoculum of
and put into cul¬

ture in this laboratory in Eagle's Minimal Essential
Medium with 17% (v/v)
essential amino acids.

fetal bovine serum,

and non-

The cells were found to grow

as rapidly in this latter medium as in the more complex

26-

-

medium containing lactalbumin hydrolysate.
Because Chinese hamsters have relatively few,
n K 11, but morphologically distinctive chromosomes
(123),

cell lines from this animal are particularly

useful in karyological studies.

The nC" clone was

selected because of its larger and more uniform size
over the parent Don line

(124).

Since the C clone in

this laboratory was found to be an unstable diploid
line,

it was recloned and a subclone with a high per¬

centage

(907o)

arid frozen.

of diploid cells was selected,

expanded

Reasonable control of genetic drift and

pleiomorphism was obtained by discarding cultures after
three weeks and replacing them with cells from the
freezer.

B.

Methods.
1.

Cell cultivation.

-- By diluting and trans¬

ferring those cell cultures carried as stock lines every
24 hours,
growth.

the cells were maintained in logarithmic
Subculture was accomplished by making a one

to four dilution of a one day old culture.

Ordinarily

7 x 106 cells were innoculated in a 16 oz. bottle con-

taining 28 ml of growth medium.

At those times when

it was necessary to renew medium, half of the spent
medium was removed and replaced with fresh medium.
Cultures were incubated at 37°

C in an atmosphere of

5% CC>2 in 95% air (Matheson; Rutherford, New Jersey).
Detachment of monolayers was accomplished by use
of one of the trypsin solutions.

Both trypsin solu¬

tions gave satisfactory results and could be distin¬
guished only by the length of time required to produce
a single cell suspension from a monolayer.

A crystal¬

line trypsin solution took about three minutes, where¬
as a Viocase solution required about 12 minutes.

The

action of both enzyme solutions was terminated by the
addition of fetal bovine serum.

A 16 oz: bottle re¬

quired seven ml of trypsin solution to cover the grow¬
ing area.

Fetal bovine serum (1.5 ml) was added

later

and the cells were collected by centrifugation.
2.

Agar cloning.

-- Cloning was accomplished by

growing cells in semisolid agar at a final concentra¬
tion of 0.165%.

A concentrated agar solution of 2.2%

was prepared by autoclaving a suspension of 0.11 gm
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of agar in five ml of 0.9% saline.
tion was stored at 4°
100°.C.

This agar prepara¬

C and liquified by heating to

After the 2.27c agar had been diluted to 0.22%

by the addition of 45 ml of complete culture medium,
it was distributed in three ml aliquots into disposable
culture tubes

(Bellco) and kept at 42°

The cells to be cloned,

C in a water bath.

in appropriate dilutions, were

added to the agar in two ml of growth medium.
providing an atmosphere of 5% CO2 in 95% air,
were closed with silicone rubber stoppers,
oughly by vortexing,

After
the tubes

mixed thor¬

and placed in an ice bath for five

minutes to accelerate gel formation.
incubated vertically at 37°

The tubes were

C.

After five days of incubation,

macroscopic colonies

recovered by aspiration (Pasteur pipette) were placed in
three ml of culture medium in 16 x 125 mm screw cap tubes
and were incubated at an angle of five degrees.

After

three days of incubation the halo of explanted cells which
surround a colony was trypsinized to provide a single
cell suspension.

The progeny of these cells provided

an innoculum of cells for experimental work.
3.

Long term storage of cells.

-- Cells were frozen

-

in ten percent (v/v) dimethylsulfoxide
cerol

(126)

(3.25) or gly¬

in complete culture medium at a level of

5 x 10^ cells per ml;
being one ml.

the usual volume in each ampule

Sealed ampules were wrapped in tissue

paper and put in a cardboard mailing carton before
being placed in a mechanical freezer (Revco; Deerfield,
Michigan) and cooled to -85°

C.

Most of the ampules

were later transferred to canes

(LabTool; Ypsilanti,

Michigan)

in the mechanical freezer, but a few were

transferred to a liquid nitrogen freezer for long
term storage.

Cells were recovered by rapidly thaw¬

ing an ampule in a 37°

C water bath.

The cell suspen¬

sion was then diluted 1 to 20 in complete culture
medium.
4.

Cell synchronization.

tions were

selected by treating 17 hour cultures with

Colcemid at 1.62 x 10" ^ M.
hours,

-- Synchronized popula¬

After an incubation of 2.5

the drug containing medium was decanted and re¬

placed with a crystalline trypsin solution.
were gently shaken for twenty seconds,
cells were collected by centrifugation.
were kept at 4°

The flasks

and the detached
These cells

C to prevent them from dividing once
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the Colceraid had been removed.

After one wash,

cells were diluted into growth medium.

the

The time at

which these cultures were returned to 37°

C was con¬

sidered the start of the experiment (t - 0).
5.

Chromosome preparations.

-- Metaphase spreads

were made from logarithmically growing cultures treated
with Colcemid

(1.62 x 10"^ M) for two hours.

The

mitotic cells were made to swell by placing them in
hypotonic solutions of either 17, sodium citrate,

or

culture medium diluted one to five with water for ten
minutes

(127).

Permanent slides were made from cells fixed with
257, (v/v) acetic acid in absolute methanol for 30 min¬
utes at 4°
fixative,

C.

After washing the cells once with the

a drop of the resuspended cell pack was placed

on a cold wet slide and blown across the slide to spread
the cells

(123).

After drying overnight,

the cells were

stained with a Giemsa solution (129) and covered with
a cover slip.
Temporary slides were made from cells fixed in
507o (v/v) acetic acid for thirty minutes at 23°
The cells were stained with aceto-orcein (27,)

C.

for five
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minutes.

A small drop of the stained cell suspension

was placed on a
coverslip,

slide,

covered with a 22 mm square

and squashed

(129).

The preparation was

sealed with hot wax (Kronig's Cement, Fisher Scienti¬
fic Company;
6.

Springfield, New Jersey).

Incorporation of radiochemicals.

-- The amount

of incorporation of isotopically labelled compounds
into the acid insoluble cell fraction was determined
by scintillation counting of the acid insoluble precipitates collected on membrane filters
an average pore size of 0.22 microns
At the end of the incubation,

(Millipore) with
(130,

131,

132).

the cells were washed

twice in situ with five ml of Hanks's solution.

Cells

were detached by treatment with a crystalline trypsin
solution and washed onto the filter with 10 ml of 0.9%
saline.

The flask and funnel of the filter holder were

rinsed with an additional 10 ml of saline.
the funnel with ice cold 3% (w/v)
(TCA),

After rinsing

trichloroacetic acid

the cells were extracted for two minutes in ten

ml of the acid solution.

The cell residue was rinsed

with 15 ml of TCA,

and placed in scintillation

dried,

vials containing ten ml of scintillation solution.

When
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the filters hacl become translucent and the vials equi¬
librated to 5°

C,

they were counted for ten minutes by

the scintillation counter.

No less than three repli¬

cate cultures were analysed per
7.

Cell fractionation.

point.

-- The amount of isotopi-

cally labelled compound in the acid soluble fraction
or in a particular macromolecular fraction (RNA, DNA,
or protein) was determined by extracting cells with
perchloric acid
(132).

(PCA)

and sodium hydroxide solutions

Cells which had been incubated with the parti¬

cular radioactive compound in the experiment were washed
twice with Hanks's solution,

and then detached by treat¬

ment with a crystalline trypsin solution.

The cells

were then carefully layered onto a three cm column of
sucrose

(0.25 M)

in a Shevky-Stafford and McNaught centri¬

fuge tube (Fisher Scientific Company) and centrifuged
for ten minutes at 700 x g.
been removed by aspiration,
with Hanks's solution,

After the supernatant had
the tube was rinsed well

and then carefully dried with

absorbent paper.
The acid soluble fraction was obtained by suspend¬
ing the cells in 0.2 N PCA for ten minutes at 4°

C.

••
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The residue containing the RNA, DNA and protein of the
cell was collected by centrifugation.

The precipitate

was washed twice with 0.2 N PCA and the washings pooled.
A fourth washing,

the soluble intermediate fraction, was

counted immediately as a control to insure that no acid
soluble radiocompound remained in the residue.
Cellular RNA was extracted by hydrolysis of the
cold acid precipitate in 0.5 ml of 0.2 N NaCH at 80°
for 20 minutes.

C

Protein and DNA were precipitated from

solution by acidifying the cold alkaline hydrolysate
with 1 N PCA to a final concentration of 0.5 N PCA.
This extraction was repeated once.
The DNA was separated from the protein by hydroly¬
sis in 1 N PCA at 80°

C for thirty minutes.

The remain-

%

ing protein precipitate was not subjected to further
treatment.

The amount of

radioactivity in each fraction

was determined by liquid scintillation counting.
8.

Paper chromatography.

-- Descending paper chro¬

matography was carried out in a solvent system of 86%
n-butanol and ammonium hydroxide in a ratio of 94.5:
(v/v)

on Whatman no.

1 paper (42).

5.5

Material to be chro¬

matographed was applied as a small spot 7,5 cm from the
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top of the sheet.

When the Rf of a particular com¬

pound was to be determined,

the chromatogram was re¬

moved and air dried when the solvent front was three
cm from the bottom of the sheet.

At times,

the sol¬

vent front was allowed to run over the free edge to
insure a good separation of all components.

Nucleo¬

sides separated in this way could be located visually
by short wave ultraviolet illumination (Ultra-violet
Products;

San Gabriel,

California).

belled compounds were run,

When radio-la-

their location was also

determined by cutting the chromatogram lane in which
they were run into small consecutive pieces

(1 or 1.5

cm) which were placed in scintillation vials,
with 0.1 ml of water,

moistened

and covered with ten ml of scintil¬

lation solution.
Preparative paper chromatography was carried out
in the same manner as analytic chromatography except
that the compound to be purified was applied in small
spots along a horizontal line 41 cm long.

After the

run had been completed and the chromatographic solvent
evaporated from the paper,
ed by drip elution.

the material run was recover¬

A blank piece of paper was eluted
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at the same time and the amount of material recovered
calculated from the optical density of the solutions.
9.

Column chromatography.

-- Phosphorylated deri¬

vatives of nucleosides were separated by ion exchange
chromatography.

ECTEOLA-cellulose was washed thorough¬

ly with 0.1 N NaOH and 0.1 N HC1, and carefully rinsed
with water until it was chloride free.

After the fines

had been removed, a column 1 x 16 cm was prepared.

Be¬

fore use the column was equilibrated with 15 ml of 0.05
M LiCl in 1 x 10"^ M Tris,

pH 7.4 (Sigma; St. Louis,

Missouri) and then with 28.0 ml of 0.0025 M LiCl in
1 x 10“^ M Tris,

pH 7.4.

The final pH of the equili¬

brating effluent was pH 6.8 - 7.2.

The material to be

absorbed on the column was diluted 1 to 20 and its pH
adjusted to 7.8.

The phosphate derivatives were eluted

with different concentrations of LiCl in 1 x 10
pH 7.4, as outlined below (42).

„3

M Tris,
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Molarity of the
Li Cl solution

Fraction

.

1

2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.

Volume of
fraction

0.0025 M
0.05 M
0.05 M
0.05 M
0.08 M
0.08 M
0.08 M

20.0
10.0
15.0
10.0
3.0
2.0
2.0

0.08
0.08
0.08
0.08
1.0
1.0
1.0

10.0
1.0
1.0
1.0
5.0
5.0
5.0

M
M
M
M
M
M
M

-

Authentic material was added as cold carriers.
Since the di- and tri-phosphate derivatives of arabinosylcytosine are not commercially available, CDP
and CTP were substituted as they behave as the corres¬
ponding arabinosyl nucleotides.

Fractions 3, 8, and

12 contained the mono-, di~, and tri-phosphate deriva¬
tives respectively.

The free nucleoside was recovered

in fraction 1.
10.

Protein determination. -- The method of Lowry

et al (133) was used to determine the protein content
of cells.

Cell suspensions were sonicated (Branson;

Stamford, Connecticut) until the cells were broken.
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III. RESULTS

A. Cell Culture
Cloninft. -- Macroscopic colonies, observable
on the fourth day of culture at 37° C, continue to grow
in size until day 11, at which time the average colony
is approximately 1 rnm in diameter,,

Cloning efficiency,

when 25 - 125 cells are innoculated, is about 65%.
Colonies are counted with the aid of a Quebec Colony
Counter (A0 0, Spencer).

Because of visual overlap,

five ml cultures with more than 60 colonies are diffi¬
cult to count accurately.

Each colony consists of the

descendants of a single cello

When a large number of

cells, on the order of 3 x 10^ cells, are planted in¬
numerable minute, colonies, which are unquestionably dis¬
crete, appear in three days0

These colonies remain

minute and do not increase in size after day 4.
Colonies recovered by aspiration cannot be broken
into single cell suspensions by vigorous pipetting or
by treatment with Viocase.

Since the colonies are archi

tecturally stable, they can be fixed in 107o formalin,
embedded, sectioned, and stained according to standard
procedures for solid tissues (Histology Section, Department of Pcithology, Yale-New Haven Medical Center).
Necrotic cells in the center of the colony, surrounded
by fusiform cells in a pattern of concentric circles,
are seen in stained sections (hematoxylin and eosin)
of five day old colonies.

Increasingly older colonies,

which are larger in size, have a concomitantly larger
necrotic center.

Because of the central necrosis in

fully grown colonies, clones were established only from
young colonies.
2.

Cellular growth. -- In liquid medium, the sub¬

clone used in these experiments has a doubling time of
11 hours (Chart 1), which is approximately the same as
that of the parent line, which has a reported doubling
time of 12 hours (110).

The cells remain in a loga-

rithmic growth phase during the first 48 hours after sub¬
culture, when the innoculum is below 4 x 10^ cells per
culture in five ml of growth medium,
3.

Synchronous growth. — After being resuspended

in growth medium free of Colcemid, the mitotic cells.

39

-

-

which comprise over 95% of the starting cell popula¬
tion, attach to the glass substrate and begin divid¬
ing 0.50 hours after being returned to 37° C.

The

initial wave of cell division is complete 0.75 hours
later (Chart 2).

No appreciable increase in cell num¬

ber takes place until after seven hours of further in¬
cubation .
Cell synchrony is monitored by direct visual ob¬
servation of the cells (inverted microscope), by closely
following shifts in cell volume (Table 1, Chart 3), and
by the determination of cell number (Chart 2).

A mean

cell volume computer (Coulter) was not always avail¬
able, but an accurate determination of volume changes
can be carried out by examination of cell size distri¬
bution plots (Chart 3).

As the mitotic cells divide,

there is an acute shift in the mean cell volume of the
population.

Although the cell number remains relative¬

ly constant during the course of the subsequent incu¬
bation of eight hours, the cells increase in volume.
As the cells proceed through the second wave of divi¬
sion, after approximately nine hours of incubation,
the mean cell volume falls again.
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CHART 1.

Growth Curve, Non-synchronized Cells.

--

Logarithmically growing cells were innoculated at 2 x 10~> cells per culture in four
ml of growth medium.

At 12 hour intervals

the number of cells per culture was deter¬
mined.

-
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CHART 2.
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Growth Curve, Synchronized Cells. -- Mitotic
cells were innoculated at 7.1 x 10^ cells
per ml, 2 ml per culture.

The number of cells

per ml was determined at intervals of time.
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CHART 3.

-

Cell Size Distribution During the Cell
Cycle. -- The size distribution of cells
described in chart legend 2 was plotted
at intervals of time (hours).
a,

These were

logarithmically growing cells (non-

synchronized); b, t = 0;

c,

c, t = 5;

t = 12;

d, t = 9;

e,

t s 1;

d, t

2;

f, t = 13.
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TABLE 1
VARIATION IN THE MEAN CELL VOLUME OF SYNCHRONIZED CELLSa

Sample

Mean Cell Volume

Logarithmically Growing Cells

110

Metaphase Cells

150

Time (hours) after
return to 37° C
0.5

152

1.0

116

2.0

124

3.0

133

5.0

148

8.0

148

9.0

151

10.0

152

11.0

145

12.0

143

13.0

132

aMetaphase cells were resuspended in Colcemid free
medium and incubated at 37° C (t - 0).

At intervals,

cultures were trypsinized and the mean cell volume of
the population was determined by use of a Coulter Mean
Cell Volume Computer.

The mean cell volumes are reported

in terms of arbitrary (machine) units.

There is

£i!

appc
>arent

failure in cellular divi¬

sion in that the cell number does not double.

This

failure in doubling is probably due to several factors,
such as the inclusion of interphase cells in the popu¬
lation,

the failure of sore cells to divide, and the

failure to recover attached cells from culture vessels.
From direct visual observation, it arrears that cost of
the mitotic cells do divide (110).

An analysis of the

shift in the distribution of cell size supports this
observation (Chart 3).

There is no complete explana¬

tion for the failure to obtain a numerically exact
doubling.

Mean cell volume and cell number were checked

in each experiment and only populations which did show
the characteristic changes cf a synchronously growing
culture were used to obtain data.
The major periods of the cell cycle were fixed
according to published reports on the behavior cf this
cell line when synchronized (123).

If the return cf

the mitotic cells to 37° C is considered the beginning
of an experiment or t = 0, then G1 was fixed at t - 1.25
to 3.0 hours; S at t = 3 to 9 hours; G2 at t = 9 to 11
hours.

Since the degree of synchronization degenerates
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markedly during the cell cycle (128), points repre¬
sentative of various stages in the cell cycle were
selected to avoid as much overlap in populations from
different stages as possible.

Representative points

for various stages were taken between t - 1.25 - 2.25
hours for Gl, t = 3.25 - 4.25 hours for the first part
of S (S-^),

t - 6.25 - 7.25 hours for the latter part

of S (S2), and t - 8.75 - 9.75 hours for G2.

B.

Incorporation of Isotopically Labeled Compounds.
Cellular uptake of isotopically labeled compounds

into the acid insoluble fraction, as determined by
scintillation counting of the precipitate trapped on
membrane filters (Millipore), is linear with respect
to the length of incubation and the concentration of a
particular radiocompound in the medium.

All incubations

with radiochemicals were carried out at 37° C.

Cultures

were innoculated at 3.0 - 3.5 x 10^ cells per five ml
of culture medium five to six hours before an experi¬
ment.

In the first set of radiochemical incorporation

experiments,

logarithmically growing cells were incubated

for fifteen minutes with different concentrations of ^H-
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deoxythymidine (Chart 4), ''H-uridine (Chart 5), or
^H-l-leucine (Chart 6).

In the second set. of exper¬

iments, the length of incubation with a particular
radiocornpound was varied whereas the concentration of
o

the radiochemical was held constant.

JH-Deoxythymi¬

dine (Chart 7) was used at a final concentration of
3.3 x KT7 M; %-uridine (Chart 8) at 2.5 x 10"7 M;
and

H-l-leucine (Chart 9) at 2y'c/ ml.

ation of

3

The incorporo

H-deoxythymidine (Chart 1C) and JH-uridine

(Chart 11) by synchronously growing populations of
cells with respect to time was then examined.

Incor¬

poration is linear.
The acid insoluble precipitate cannot be removed
from the filter by vigorous shaking in the scintillation
solution (Table 2).

Orientation of the filters, precipi¬

tate up or down, is not important as long as the filters
are not counted before becoming translucent and are vigor¬
ously shaken in the scintillation solution before count¬
ing.

Extraction of the acid insoluble precipitate with

1 N PCA at 80° C increases the absolute count, and re¬
leases the incorporated radiochemical into the scintil¬
lation solution, presumably by hydrolysis of the DNA
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CRART 4.

Incorporation of

H-deoxythymidine into

Logarithmically Growing; Cells. - - Cells
were innoculated at 3.5 x 10

cells per

culture six hours before ^H-deoxythymidine
(3c/ mmole) was added at different concen¬
trations.
pound

Incubations with the radiocom¬

were held constant at 15 minutes.

The standard error of the mean is indicated.
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a
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CHART 5.

Incorporation of

H-uridine into Logarith¬

mically Growing Cells. -- Cells were innoculated at 3.5 x 10^ cells per culture six
hours before ^H-uridine (Sc/mmole) was added
at different concentrations.

Incubations

with the radiocompound were 15 minutes.
standard error of the mean is indicated.

The
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CHART 6.

Incorporation of

3

H-l-leucine into Logarith¬

mically Growing Cells. -- Cells were inuoau¬
la ted at 3.0 x 10^ cells per culture 5.25
hours before ^H-l-leucine (6c/mraole) was added
at different concentrations.

Incubations with

the radiocompound were held constant at 15
minutes.
indicated.

The standard error of the mean is

f
o

8000

o

CHART 7

Incorporation of -H-Deoxythymidine into
Cells♦ -- Logarithmically growing cells
were innoculated at 3.5 x 10^ cells per
culture six hours before
dine (3c/mmole, 3.3 x 10

H-deoxythymi”'

M) was added.

The length of incubations was varied.
The standard error is indicated.

CHART 8.

Incorporation of

3

H-uridine into Cells.

Logarithmica 1.ly growing cells were innoculated at 3.5 x 10~* cells per culture six
hours before ^H-uridine (Sc/mmoie, 2.5 x 10”^
M) was added.

The length of incubation with

the radiocompound was varied.
error of the mean is indicated.

The standard
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CHART 9.

Incorporation of

H-l-leucine into Cells.

--

Logarithmically growing cells were innociliated
at 3.0 x 10^ cells per culture 5.25 hours beo

fore JH-1-leucine (6c/mmole) was added at a
level of 2.0 y^c/ml.

The length of incuba¬

tions with the radiocompound was varied.
standard error of the mean is indicated.

The
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'CHART 10.

Incorporation of %.~Deoxythymidine into
Synchronized Cells. -- Mitotic cells
were innoculated at 3.0 x 10J cells per
o

culture 5.25 hours before ^H-deoxythymidine (3c/mmole, 3.3 x 10“7 M) was added.
The length of incubation with the radio¬
compound was varied.

The standard error

of the mean is indicated.

CHART 11.

Incorporation of ^H-uridine into Synchronized
Cells.

-- Mitotic cells were innoculated at

3.0 x 10^ cells per culture 5.25 hours before
%-uridine (8c/mmole, 2.5 x 10"^ M) was added.
The length of incubation with 'the radiocom¬
pound was varied.
mean is indicated.

The standard error of the

4

4

*

-5 5

-

TABLE; 2

EFFECT OF FILTER ORIENTATION ON COUNTING EFFICIENCY3
CPM with S.E.
Orientation of
the filter

Before
agitation

After
agitation

Filter
removed

Precipitate up

1.467 + 27

1789 + 10

4

|

Precipitate down

1584 ± 319

1771 ± 67

2

|

mean of both
sets of filters

1525 ± 145

1780 ± 31

3

aLogarithmically growing cells were subcultured at
3.5 x X0J cells per culture six hours before
thymidine (3c/mroole, 3.3 x 10”^ H) was added.

IL-deoxyAfter incu¬

bation of the cells for 15 minutes with the radiocompound,
the acid insoluble precipitate was collected on a membrane
filter.

Filters were placed at the bottom of scintillation

vials with the precipitates either on the upper or lower
surface of the filter, and then covered with the scintilla¬
tion solution.

The vials were gently shaken and the radio¬

activity determined by liquid scintillation counting.

The

vials were then vigorously reshaken with no effort made to
keep the precipitates oriented in any one direction.

After

recounting, the filters were removed and the solutions re¬
counted .
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(Table 3).
point,

Since control cultures were run at each

internal quenching as a factor influencing

counting efficiency was largely compensated for.
As the acid insoluble material trapped on the
filter is composed of the protein, RNA and DMA of the
cell, it was determined by scintillation counting of
cell fractions (PCA-NaOH) that more than 94% of the
incorporated ^H-deoxythymidine is in the cell’s DNA,
o

and more than 95% of the incorporated JH-uridine is
in the cell’s RNA (Table 4).

C.

Reduction of Arabinosylcytosine Concentration by
Washing.
Using ^H-arabinosylcytosine, the effectiveness

of washing procedures was determined.

The most effi¬

cient method was to pour off the drug containing medium,
and shake, to dislodge the last drops of medium.

The

above procedure was repeated by adding one volume of
medium per wash until the desired final drug concentra¬
tion was obtained.

Reduction in drug concentration is

exponential (Table 5, Chart 12), and the loss of cells
with repeated washings is minimal.

In all experiments,

however, controls were run to insure that not more than
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TABLE 3

EFFECT OF HOT ACID EXTRACTION OF
FILTER COLLECTED PRECIPITATES3

St

Acid insoluble precipitates were labeled and col¬

lected exac tly as described in Table 2.
ters was counted directly.

One set of fil¬

To each of the filters of the

second set was added 0.2 ml of 1 N PCA.

After these fil¬

ters had been incubated at 80° C for 15 minutes, they
were suspended in scintillation solution and counted (A).
In another set of acid insoluble precipitates hydrolyzed
with 0.2 ml of 1 N PCA,

the filters were removed after be¬

ing counted and the radioactivity remaining in the scintil¬
lation solution was determined (B).
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TABLE 4

INCORPORATION OF RADIOCOMPOUNDS
INTO DNA AND RNAa

CPM
F raction
soluble

^H-deoxythymidine

^H-uridine

9250

104,981

61

198

RNA

1618

45,026

DNA

29,973

135

soluble
intermediate

3
~TI-deoxy thymidine present in RNA fraction - 5.1%
3

H-uridine present in DNA fraction - 0.33%
Cells (3.89 x 10^) in early S were- labeled with

%-deoxythymidine (3c/mmole, 3.3 x 10*"^ M), Cells (5.63 x
106) in early S were labeled with ^H-uridine (8c/mmole,
2.5 x 10 ^ M).

The length of incubation with the radio¬

compounds was 15 minutes.

The cells were fractionated

(PCA-NaOH) and the amount of radioactivity in each frac¬
tion determined.
experiments.

The cells were gathered in separate

*
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TABLE 5

REDUCTION OF 3H-ARABXNOSYLCYTOSXNE
CONCENTRATION BY REPEATED WASHINGS3

Wash

CPM per 0.2 ml sample
with S. E.

incubation

277,200 + 3100

Drug con¬
centration (M)
1.00 x 10"4

1

11,718 +

877

3.11 x 10~6

2

606 +

53

1.61 x 10~7

3

42 +

2

1.11 x 10“8

aCelIs (3.5 x 103) in logarithmic growth were
innoculated in five ml of culture medium before 3Karabinosylcytosine (50y^c^Amole,

1 x 10~4 M) was added.

The cells were washed repetitively with one. volume of
medium and

the radioactivity of a 0.2 ml sample was de¬

termined by liquid scintillation counting.
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wash

CHART 12.

Reduction of ^H-Arabinosylcytosine by
Repeated Washings.

--

Cells (3.5 x 10^) in

exponential growth were innoculated in five
ml of medium before "'H-arabinosycytosine
mole,

1 x 10~^ M) was added.

The

cells were washed repetitively with one
volume of growth medium and the radioactivity
of a 0.2 ml sample was determined by liquid
scintillation counting.

61-

-

five percent of the cell population was lost by wash¬
ing.

All comparisons of drug treated cells are based

on control cell populations washed in a similar manner.

D.

Effect of Arabinosylcytosine on Logarithmically
Growing Cells.
The effect of the continuous presence of arabino¬

sylcytosine on logarithmically growing cells was deter¬
mined in order to find a drug level which would stop cel¬
lular multiplication (Chart 13).

The shape and position

of the curve with respect to arabinosylcytosine concen¬
tration is approximately that reported for other cell
lines (18).
Since the length of treatment in experiments using
synchronous populations of cells was to be limited to
one hour in each of the various periods of the cell cycle,
the effect of one hour's treatment with arabinosylcytosine
on random cells was studied.

In all experiments, with

either random or synchronized cells, the effect of one
hour's treatment with arabinosylcytosine on the ability
of the cells to multiply is reported as the percentage
of the number of cells present, after two days incubation,
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CHART 13.

Survival cf Arabinosylcytosine Treated
Cells. -- Cells were innoculated at 1.9 x 10^
cells per culture.

Arabinosylcytosine was

added at different final concentrations.

After

two days of incubation, the number of cells per
culture was determined.
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as compared with the non-ara-C treated control cultures
(100% outgrowth).

The starting innoculum ranged from

2.0 x 105 to 3.5 x 10^ cells per culture, in five ml
volume of growth medium.

The final cell number after
c.

two days of growth in controls was between 4.0 x 10
and 6 x 10^ cells per culture.

Experiments in which

control cultures failed to reach this level of out¬
growth were discarded.
Rescue means that cells treated with arabinosylcytosine

are first washed before a second compound(s)

is added to the culture medium.

Protection means that

cells treated with arabinosylcytosine are provided with
a second compound(s) both during drug treatment and
after the cells have been washed.
With nonsynchronized cells, one hour’s treatment
with arabinosylcytosine at a final concentration of
_r

1 x 10
6).

M has little effect on cellular outgrowth (Table

At 1 x 10”"* M, arabinosylcytosine reduces cellular

outgrowth (Table 6).

Rescue and protection of drug

treated cells by a mixture of all deoxynucleosides re¬
quired for DNA synthesis (deoxythymidine, deoxyadenosine,
deoxyguanosine, each at 1 x 10~D M; and deoxycytidine at

4

-
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TABLE 6

EFFECT OF ANCILLARY TREATMENT ON
ARABINOSYLCYTOSINE TREATED LOGRITHMICALLY
GROWING CELLSa
l

Ara-C concentration (M)

Ancillary
treatment

Percentage
Outgrowth

final

initial
1.0 x 10~4

1.5 x 10”7

protection

98

1.0 x 10”5

1.1 x 10~8

none

33

rescue

84

protection
1.0 x 10"6

3.

< 1.0 x 10“8

none

100
89

S

Cells (3.11 x 10J) were subcultured three hours

before arabinosylcytosine was added at different final
concentrations.

After one hour, the concentration of

drug was reduced as indicated, and some cultures were
rescued, or protected by a deoxynucleoside mixture
(dGuo, dThd, dAdo, each at 1 x 10~8 M; dCyd at 5 x 10"-* M).

5 x 10**5 M), however, is good (Table 6).

Protection

is virtually complete even in cells treated with ara-C
at 1 x 10"4 M (Table 6).

E.

Effect of Arabinosylcytosine on Synchronously Grow¬
ing Cells.
1.

Growth of cells treated with arabinosylcyto¬

sine . -- Arabinosylcytosine at concentrations as high
as 1 x 10”^ M does not greatly inhibit the ability of
G1 cells treated for one hour to grow (Table 7).

G1

cells initially treated with ara-C at 1 x 10*’4 M for
an hour, and then incubated with arabinosylocytosine at
a concentration of 1 x 10”

M grow with the same doubling

time as non-treated controls (Chart 14).
Cells treated during S or G2 are markedly in¬
hibited by an initial incubation with arabinosylcyto¬
sine at 1 x 10”4 M for one hour, and subsequently at
1 x 10“® M.

(Table 7).

Morphol ogically these cells

were bizarre in shape, with many round and granular cells,
when seen two days after drug treatment.
2.

Effect of deoxynucleotaides on the growth of

cells treated with arabinosylcytosine for one hour .
Cells in G1 treated with arabinosylcytosine at 1 x 10”4
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TABLE 7
EFFECT OF ARABINOSYLCYTOSINE
ON SYNCHRONOUSLY GROWING CELLSa

Ara-C concentration (M)

Percentage
outgrov?th

final

initial
1.0 x 10~3

1.0 x 10~4

p

State at
treatment

1.1 x 10"8

M

59

<1.0 x 10~8

G1

60

1.1 x 10“8

G1

40

<1.0 x 10”8

S

<1.0 x 10~8

G?.

8
10

Cells were incubated for one hour with

arabinosylcytosine at the indicated concentrations
during different stages of the cell cycle.

The

final drug concentrations were attained by appropriate
washing of the cells.
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CHART 14.

20

I

40
TIME IN HOURS

60

Growth of G1 Cells After Treatment with
Arablnosylcytosine. -- Motaphase cells
r

innoculated at 2.5 x 10"'

cells per cul-

tore V7ere incubated with arablnosylcytosine
at 1.0 x 10“^ M for one hour, during Gl.
After the initial drug treatment, the con¬
centration of the drug was reduced to
1.1 x 10

-ft

M by washing the cells.

Non¬

drug treated cultures served as controls.
At intervals of time, the number of cells
per culture was determined.

8-
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M for one hour, and subsequently cultured with arabinosylcytosine at

lx 10“' M and deoxycytidine at

3. x 10~^ M grow well, with the same doubling time as
normal (control) cells (Chart 15).

Other deoxynucleo-

sides (dThd, dAdo, and dGuo) can not replace deoxycyti¬
dine (Table 3).

S and G2 cells do not grow when treated

with arabinosylcytosine initially at 1 x 10”^ M for one
hour, and then cultured with either a mixture of deoxynucleosides or deoxycytidine at 5 x 10**^ M and arabino¬
sylcytosine at 1 x 10“ ^ M (Table 8).
The presence of deoxycytidine at 1 x 10“^ M does
not significantly affect cell growth (Table 9).

The

mere addition of deoxycytidine does not permit arabino¬
sylcytosine treated G1 cells to grow (Table 10).

The

concentration of arabinosylcytosine in the incubation
medium must first be reduced.
3•

Effect of the simultaneous addition of deoxy¬

cytidine with arabinosylcytosine on cell growth. -- Cells
at all stages of the cell cycle, when incubated with ara¬
binosylcytosine and deoxycytidine each at 1 x 10"^ M,
for one hour, and then with ara-C at 1 x 10“^M and de¬
oxycytidine. at 1 x 10'^ M, grow well (Table 11).

Nucleo-

o CONTROL
• ARA-C
TREATED

10

20

40

60

TIME (HOURS)

CHART 15.

Growth of Rescued Cells Treated with
Arabinosylcy t.osine in G1. -- Metaphase
cells innoculated at 2.5 x 10^ cells
per culture were incubated with arabinosylcytosine at a final concentration of
1 x 10”^ M for one hour in Gl.

The drug

concentration was reduced to 1.6 x 10“^ M,
and deoxycytidine (lx 10~^ M) was added.
At different intervals of time, the number
of cells per culture was determined.

Non¬

drug treated cultures served as controls.

**

TABLE 8

EFFECT OF DEOXYNUCL.EOSIDES ON TEE OUTGROWTH
OF ARABINOSYLCYTO SINE TREATED CELLSa
Stage at
treatment
Gl

-

S

G2

Percentage
outgrowth

Ancillary treatment
none

7

rescue with dThd, dAdo,
and dGuo

7

rescue with dThd, dAido,
and dCyd

76

rescue with dCyd, dA.do,
and dGuo

75

rescue with dCyd

85

none

5

rescue with dCyd, dThd,
dAdo, and dGuo

20

rescue with dCyd

21

rescue with dThu, dAdo,
dGuo, and dCyd

33

Synchronized cells in Gl, S and G2 were treated
with arabinosylcytosine (1 x 10”^ M) for one hour.

De-

oxynucleosides were used at the following final concerttrations:

dGuo, dThd, and dAdo each at 1 x 10

deoxycytidine at 5 x 10“^M.

M; and

Cells were rescued by re**
_ *7

ducing the drug concentration to 1 x 10
adding deoxynucleosides to the

medium.

M, and then
Cultures

were innoculated at 3,20 x 10”^ cells per culture and
harvested after two days.
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TABLE 9

EFFECT OF DEOXYCYTIDINE ON THE OUTGROWTH
OF SYNCHRONIZED CELLSa

Presence of
deoxycytidine

+

Number of cells
per culture

4.91 x 106
4.88 x 106

aDeoxycytidine (lx 10“^ M) was added to syn¬
chronously growing cells in Gl.

Cultures innoculated

with 2.5 x 10^ cells were counted after two days.
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TABLE 10

EFFECT OF DEGXYCYTIDINE ON ARABINOSYLCYTOSINE
TREATED CELLS3

Stage at
treatment

number 'of cells

G1

4.16 x 105

Si

2.83 x 105

control

5.75 x 106

Synchronously growing cells (4.0 x 10^ cells
per culture) were incubated with arabinosylcytosine
(lx 10”

for one hour during G1 or Sp

Without

removing the drug, deoxycytidine (lx 10~^ M) v?as added.
The cultures were incubated for tv?o days and then
counted.
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TABLE 11

EFFECT

OF DEOXYCYTIDINE AND NUCLEOSIDES

ADDED WITH ARABINOSYLCYTOSXNEa

State at
trea tment

Ancillary
agent

Percentage
outgrowth

G1

deoxycytidine

94

si

deoxycytidine

95

s2

deoxycytidine

96

G2

deoxycytidine

99

Ado, Gdo, Thd, Cyd

14

S

aMetaphase cells (2.5 x 10^) were treated during
their subsequent cell cycle with arabinosylcytosine
(1.0 x 10”4 M) for one hour at the stage indicated.
Deoxycytidine (1.0 x 10"^ M) or a mixture of nucleo¬
sides with deoxythymidine (Ado, Gdo, Thd and Cyd all at 5 x 10"6 M) were added along with the drug.
After the initial drug treatment, the concentration
of the drug was reduced to 1.6 x 10 ^ M, whereas the
concentration of deoxycytidine or the nucleosides was
maintained unchanged throughout the subsequent incuba
tion.
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sides (Cyd, Ado,

and Guo) with deoxythymidine are un¬

able to protect drug treated cells

(Ta.ble 11).

After

the reduction in arabinosylcytosine concentration, the
deoxycytidine concentration in the final incubation
medium need not be maintained at 1 x 10”'^ M (Table 12).
o

4.

Accumulation of

H-arabinosylcytosine in cells

incubated with deoxycytidine.
(1 x ICf4 M)

is present in the growth medium,

a 95% reduction of
tion (Table

-- When deoxycytidine

13).

there is

K-ara-C in the acid soluble frac¬
The intracellular concentration of

arabinosylcytosine in protected cells was 8.05 x 10”^
M, whereas in unprotected cells it was 1.88 x 10”4 M.
5.

Growth of cells incubated with arabinosylcyto-

sine at 1 x 10"

M, and deoxycytidine.

-- Cells at all

stages of the cell cycle, when incubated with arabinosylcytosine at 1 x 10”

M for one. hour,

and then with ara-C

at 1 x 10”6 M and deoxycytidine at 1 x 10”4 M grew well
(Table 14).
6•

Phosphorylation and incorporation of ^H-ara-

binosylcytosine by cells.

-- Separation of

H-arabino-

sylcytosine from its phosphorylated derivatives by means
of ECTEOLA - cellulose columns shows that the drug is
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TABLE 12

EFFECT OF DEOXYCYTIDINE ON ARABINOSYLCYTOSINE
TREATED CELLSa

Ancillary
treatment

Percentage
outgrowth

deoxycytidine only
during ara-C treatment

13

protection, deoxycytidine
for one hour after drug
removal

81

protection

91

aSynchronously growing cells in early S were
treated with arabinosylcytosine
hour.

(lx 10^! M)

for one

One set of cultures was protected with deoxy-

cytidine

(lx 10"^ M) only during drug treatment.

another set of cultures,

after the drug concentration

had been reduced to 1.6 x 10”
deoxycytidine

In

M,

the incubation with

(1 x 10“^ M) continued for another hour.

The cells of the last set of cultures /protection/
were continuously incubated in the presence of deoxy¬
cytidine

(1 x 10“4 M).
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TABLE 13

EFFECT OF DEOXYCYTIDINE ON THE AMOUNT OF
%-ARABINOSYLCYTOSINE IN THE ACID SOLUBLE FRACTION8
CPM
deoxycytidine

-

4-

Fraction

acid soluble
acid insoluble

aCells

(3.42 x 10^)

372

8376

30

113

in early S

were

treated for one hour with

arabinosylcytosine

(30^0/^ mole,

The cells were fraction¬

1 x 10“4 M).

ated and the radioactivity in each fraction determined.
Some of the cultures were protected with'deoxycytidine
(1 x 10"4 M).
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TABLE 14

GROWTH OF CELLS INCUBATED WITH
ARABINOSYCYTOSINE AND DEOXYCYTXDXNEa
-—-———■—--——
Stage at
treatment

Concentration
of dCyd (M)

Percentage
Outgrowth

G1

1 x 10~4
1 x 10"5
1 x 10"6

83
43
7

S

1 x 10“4
1 x 10~5
1 x 10“6

81
43
7

G2

1 x 10“4

86

aCells were treated with arabinosycytosine
(lx 10“ ^ M) for one hour at the stage of the cell
cycle indicated.

After the one hour treatment,

the

drug was not removed, but deoxycytidine was added
at the indicated final concentration.

After two

\

days,

the number of cells per culture was determined.
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phosphorylated to a significant extent.

More than

90% of the drug in the acid soluble fraction is re¬
covered as the di- and tri-phosphate derivatives
15 and

16).

(Table

There appears to be some incorporation of

the drug into the acid insoluble fraction of the cell
(Table 15).

No conclusions are drawn from this finding

since the radioactivity of each insoluble fraction (RNA
and DNA) was very low;

counts were less than twice

back¬

ground .
7•

Accumulation and phosophorylation of deoxycy-

tidine and deoxythymidine by arabinosylcytosine. treated
cells.

-- The amount of ^H-deoxythymidine accumulated

by arabinosylcytosine treated and control cells in the
acid soluble fraction is the same

(Table -17).

sylcytosine appears to stimulate, however,
tion of exogenous deoxycytidine

(Table 18),

Arabino-

the accumula¬
and does

not inhibit its phosphorylation (Table 19).
8.
Cells,
sine,

Loss of pyrimidine nucleosides from cells.

--

incubated with deoxythymidine and arabinosylcyto¬
and then washed free of these compounds,

decrease

the amount of drug previously accumulated in their acid
soluble pool,

(deoxythymidine,

Table 20;

ara-C,

Tables

■*

TABLE 15

ACID SOLUBLE 3H-ARABINOSYLCYTOSINEa

*"
CPM
Sj

cells

Fraction

G1 cells

soluble

11,000

22,800

45

144

126

221

soluble
intermediate
acid insoluble

a10.8 x 10^ cells in G1 or

were incubated

for one hour with 3H~ara-C (40/4C//<-mole,
The amount of

1 x 10“^ M).

H-ara-C in the acid soluble and acid

insoluble fractions was determined by scintillation
counting.
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TABLE 16
PHOSPHORYLATION OF 3H-ARABINOSYLCYTOSINEa

CPM
G1 cells

Fractions

S-| cells

30

50

di- and tri¬
phosphate

3742

3334

Total

3957

3702

mono-pho spha te

Percentage as the
di- and tri-phosphate
derivatives

90%

95%

aThe acid soluble fraction described in Table 15
was subfractionated on ECTEOLA-cellulose columns in
order to separate the mono-,
derivatives of

di -,

and tri-phosphate

H-arabinosylcytosine from the free

o

H-arabinosylcytosine,
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TABLE 17

EFFECT OF ARABINOSYLCYTOSINE ON THE AMOUNT OF
3H-DEOXYTHYMIDXNE IN THE ACID SOLUBLE FRACTION3

A

o

5.75 x 10
3H-deoxythymidine
minutes.

cells in S-^ were incubated with
(3c/mmole,

3.3 x 10“^ M) for 20

A parallel set of cultures was simultaneously

treated with arabinosylcytosine
incubation with the
tionated

(1 x 10~"!' M).

radiochemical,

After

the cells were

with PCA and the radioactivity of each

fraction determined.

frac¬
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TABLE 18

EFFECT OF ARABINOSYLCYTOSINE ON THE AMOUNT OF
3H-DEOXYCYTIDINE IN THE ACID SOLUBLE FRACTION3

CPM

Fraction
Control

ara-C treated

acid soluble

9,795

15,150

acid soluble
intermediate

48

70

22,036

1,497

acid insoluble

^Synchronously growing cells

(5.84 x 10^)

in

early S were pretreated for twenty minutes with ara-C
^A

(1 x 10
(5c/mmole,

o

M).

Incubation with JR-deoxycytidine

4.0 x 10'^M) was

15 minutes.

The amount of

3H-deoxycyti.dine in the acid soluble and acid insoluble
fractions was determined by scintillation counting.
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TABLE 19

PHOSPHORYLATION OF 3H-DEOXYCYTIDINE BY
ARABINOSYLCYTOSINE TREATED CELLSa

Percentage
of total
radioactivity

CPM

Fraction
^H-deoxycytidine

9470

44.0

^H-dCMP

150

0.7

3H-dCDP

1320

^H-dCTP

9175

Total

6.15
43.0

21,424

aAfter cells (7.9 x 10^)

in early S were pre-

treated for ten minutes with arabinosylcytosine at a
final concentration of 1 x 10~4 M,
(5c/ mmole,

4.0 x 10”^ M) was added.

"’H-deoxycytidine
After a twenty

minute incubation with the radiocompound,
were extracted with cold 0.2 N PCA.

the cells

^H-Deoxycytidine

and its phosphorylated derivatives were separated on
ECTEOLA-cellulose columns.
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TABLE 20

LOSS OF 3H~DEOXYTHYMIDINE FROM CELLS

CPM

Delayed
Immediate
assay

Fraction

soluble

30,

RNA
DNA

108,

aCells

(7.54 x 10^)

494

1,

354

272

6,

480

322

116,

683

in S were incubated for

twenty minutes with 3H-deoxythymidine
3.3 x 10"^ M).

assay
(1 hr)

(3.0 c/mmole,

The first sample was fractionated

immedately following incubation.

The second sample

was washed and reincubated for one hour before
fractionation

-

21 and 22) have an effect on the loss of ara-C from
cell (Table 22).

Initial and final intracellular drug

concentrations in unprotected cells are 1.88 x 10~'! M
and 3.85 x 10“^ M respectively.

The drug is apparently

released into the incubation medium (Chart 16).
9•

Effect of arabinosylcytosirte on DNA synthesis.

-- G1 cells, treated with arabinosylcytosine at 1 x 10“^
M for one hour, and then with ara-C at 1 x 10 ^ M and
deoxycytidine at 1 x 10”^ M; S cells, treated with ara¬
binosylcytosine at 1 x 10"^ M for one hour, and then
with ara-C at 1 x 10”^ M and dCyd at 1 x 10”^ M, are
initially inhibited in their incorporation of ~H-deoxythymidine.

In time these cells recover their ability

to incorporate the radiochemical (Charts 17 and 18 re¬
spectively), and grow well.
G1 or S cells, incubated with arabinosylcytosine
at 1 x 10”^ M and deoxycytidine at 1 x 10“^' M for one
hour, and then with arabinosylcytosine at 1 x 10”^ and
deoxycytidine at 1 x 10

-4

M, are at first markedly de-

pressed in their ability to incorporate
dine.

H-deoxythymi-

After the concentration of ara-C has been reduced,

however, these cells regain their capacity to incorporate
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TABLE 21

CLEARANCE OF 3H-ARABINOSYLCYTOSINE FROM
THE ACID SOLUBLE FRACTION3

CPM
Time (hours)
at assay

2.25

4.25

Ancillary
treatment

none

rescue

j

7]
6.25

rescue

6.25

non'e -

Fractions
Acid soluble

6177

892

218

758

Acid soluble
intermediate

20

14

4

13

acid insoluble

42

40

62

55

Synchronously growing G1 cells (7.9 x 10” cells)
were incubated with 3ll-arabinosylcytosine (15.4^C/yH-mole,
1 x 10”^ M) for one hour.

The drug concentration was re¬

duced to 1.6 x 10~^ M and deoxycytidine (lx 10“^ M) was
added to some of the cultures.

At the times indicated

the amount of radiocompound in the acid soluble and in¬
soluble fractions was determined by scintillation count¬
ing.
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TABLE 22

CLEARANCE OF 3H-ARABINOSYLCYTOSINE FROM THE ACID
SOLUBLE FRACTION3

CPM
Time (hours)
at assay

4.20

4.20

5.20

5.20

Ancillary
treatment

none

protection

none

protection

Fraction
Acid soluble

8376

372

171

260

113

30

60

43

Acid insoluble

aCells (3.42 x 10^) in early S were treated with
3H-arabinosylcytosine (30y^- CJJ* mole,
hour.

1 x 10"^ M) for one

Some of the cultures were protected with deoxycyti

dine (1 x 10"^ M).

Two cultures were fractionated immed-

iately after drug treatment (t - 4.20).

The drug concen¬

tration in the other cultures was reduced to 1.6 x 10”^ M
before a further incubation of one hour.

At the times in

dicated, cells were fractionated (PCA) and the radioacti¬
vity in each fraction determined.

HD3

30

60

90

120

TIME IN MINUTES

Culture Medium. -- Cells (5,18 x 10^) in S

The cells were then washed with medium,
a.

At intervals, the radioactivity in the

culture medium was determined,

b. After one

hour the cells were washed again, and incubated
further.

The drug’s radioactivity in the cul¬

ture medium was determined at intervals.
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CHART 17.

Incorporation of ^H-Deoxythymidine into Rescued.
Cells Treated with ArabinosyIcytoslne in G1. --Synchronously growing cells (5.11 x 10^) were
incubated with arabiriosylcytosine (lx 1.0”4 M)
for one hour during Gl.

After the concentration

had been reduced to 1.6 x ICT^ M, deoxycytidine
(1 x 10"4 M) was added to all cultures.

At in¬

tervals, the ability of the cells to incorporate
^H-deoxythyraidine (3c/ramole, 4.25 x 10" ? M) was
determined.

The cells were incubated with the

radiochemical for 15 minutes.

The discontinuity

of the curve indicates that the incorporation of
the radiochemical is affected by the increase in
the concentration of exogenous deoxycytidine.

The

outgrowth of rescued cultures was 68% that of eonti
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CHART 18.

Incorporation of %--Deoxythymidine into Cells
Incubated with Arabinosylcytosine and Deoxycytidine. -- Synchronously growing cells
(6.32 x 10^) were incubated with arabinosyl¬
cytosine (lx 10”^ M) beginning in S.

After

one hour, deoxycytidine (lx 10~^ M) was added
to all cultures.

At intervals, cellular incorpor¬

ation of ^H-deoxythymidine (3c/mmole, 4.25 x 10”^
M) was measured.

The cells were incubated with

the radiocompound for ten minutes.

The out¬

growth of drug treated cells was 79% that of the
controls.
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the radiochemical (Charts 19 and 20 respectively), and
grow well.
Cells in G1 or S, treated with arabinosylcytosine
at 1 x 10”4 M for one hour, and then incubated with ara-C
at 1 x 10“7 M, do not incorporate ^H-deoxythymidine to
a significant extent at any time (Chart 21, and Table
23).

S cells, treated with arabinosylcytosine at

1 x 10"4 M, and then ara-C at 1 x 10~7 M and deoxycytidine at 1 x 10~4 M, also do not incorporate the radio¬
compound (Chart 22).

The survival of all of these cells

under the above conditions is limited.
10.

Effect of arabinosylcytosine on RNA and pro¬

tein synthesis.

-- G1 and S cells, treated with arabino¬

sylcytosine at 1 x 10”4 M for one hour, and then incubated
-7
with the drug at 1 x 10 ' M, are not significantly altered
O

in their incorporation of -H-uridine (Charts 23, and 24
O

respectively) and “Ti-l-leucine (Charts 25 and 26 respec¬
tively) .

The survival of all of these cells under the

above condition is limited.

Such cells do not divide

after treatment, but increase in volume and protein
(Table 24).

On the other hand, cells in Gl, treated with

arabinosylcytosine at 1 x 10

-4

M for one hour, and then

-yy.-
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CHART 19.

Incorporation of

H-Deoxythymidine into

Protected Cells Treated with Arabinosylcytosine in Gl. -- Synchronously growing cells
(5.67 x 10 ) were incubated for one hour with
arabinosylcytosine (1 x 10" ^ M) during Gl.
All cells were given deoxycytidine (1 x 10“Z: M).
At the end of one hour, the drug concentration
was reduced to 1.6 x

10**

7 M.

At intervals, the

ability of the protected and control cultures
to incorporate ^H-deoxythymidine (3c/mmole, 0.5 x
10"7 M) was determined.

The cells were incubated

for 15 minutes with the-radiocompound. The out¬
growth of protected cells was 8970 that of controls.
The standard error of the mean is indicated.

CHART 20.

Incorporation of -^K-Deoxythymidine into Protected
Cells Treated with Arabinosylcytosine in S.

--

Synchronously growing cells (5.26 x 10^) were
incubated for one hour with arabinosylcytosine
(1 x 10 ^ M) during S^.

All cells were given

deoxycytidine (1 x 10"“' M).

At the end of one

hour’s treatment, the drug concentration was re¬
duced to 1.6 x 1Q“7 M.

At intervals, the ability

of protected and control cultures to incorporate
^H-deoxythymidine (3c/mmole, 0.5 x 10“7 M) was
determined.

The cells were incubated for 15

minutes with the radiocompounds.

The outgrowth of

protected cells was 91% that of controls.
standard error of the mean is indicated.

The

*
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CHART 21.

Incorporation of ^H-Deoxythymidine into Cells
Treated with Arabinosylcytosine in Gl. -- Syn¬
chronously growing cells (4.45 x 10^ cells) were
treated with arabinosylcytosine (8.5 x 10“^ M)
for one hour during Gl.

After one hour, the

drug concentration was reduced to 1 x 10~7 M.
intervals, the ability of drug treated and control cells to incorporate

H-deoxythymidine

(3c/mmole, 3.3 x 10"^ M) was determined.

The

cells were incubated for ten minutes with the
radiocompound.

At

$

\

TABLE 23

INCORPORATION OF 3H-DEOXYTHYMIDINE BY
RESCUED CELLS ARABJ.NOSYLCYTOSINE TREATED IN Sa

CPM with S.E.
Time at assay
(hours)

control

ara-C treated

2.25

2158 + 99

17+2

5.25

1614 + 150

8.0

1348 + 122

24+1

11.0

900 + 136

78+8

2 + 0.3

aCells (3.67 x 103) treated with arabinosylcytosine
(lx 10~^ M) in S and then rescued, by decreasing the
drug concentration to 1.6 x 10“^ M and adding deoxycytidine (lx 10 ^ M), were incubated with 3H-deoxythyrnidine
(3c/mmole, 4.0 x 10“^ M).

Radioactivity in the acid in¬

soluble precipitate was determined by liquid scintillation
counting.

v*
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CHART 22.

Incorporation of

3

H-deoxythyroidine into Cells

Treated with Arabinosylcytosine in S. -- Syn¬
chronously growing cells (3.5 x 10^) were
treated with arabinosylcytosine (8.5 x 10"
for one hour during S.

M)

After one hour, the

drug concentration was reduced to 1 x 10

M.

At intervals, the ability of drug treated and
control cells to incorporate

H-deoxythymidine

(3c/mmole, 3.3 x 10“^ M) was determined.

The

cells were incubated for ten minutes with the
radiocompound.

iLl
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CHART 23.

Incorporation of ^H-Uridine into Cells Treated
with Arabjnocylcytosine in Gl. -- Synchronously
r

growing cells (5.18 x 10 ) were treated with arabinosylcytosine (lx 10“^ M) for one hour during
Gl.

After one hour, the drug concentration was

reduced to 1.6 x 1.0

-7

M.

At intervals the abil¬

ity of drug treated and control cells to incorporate

3

H-uridine (8c/mraole, 2.5 x 10

determined.

-7

M) was

The cells were incubated for ten

minutes with the radiocompound.
error of the mean is indicated.

The standard

CHART 24.

Incorporation of %-Uridine into Cells Treated
with Arabinosylcytosine in S. -- Synchronously
growing cells (3.17 x 10^) were treated with
arabinosylcytosine (lx 10”^ M) for one hour
during S^.

After one hour, the drug concentra¬

tion was reduced to 1.6 x 10" ^ M.

At intervals

the ability of drug and control cultures to incorporate JH-uridine (8c/mmole, 2.5 x 10”7 M)
was determined.

The cells were incubated for

ten minutes with the radiocompound.
error of the mean is indicated.

The standard

*
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CHART 25.

Incorporation of %-1-Leucine into Cells
Treated with Arabinosylcytosine in Gl. -Synchronously growing cells (4.95 x 10^)
were treated for one hour with arabinosyl¬
cytosine (1 x 10”^ M) during Gl.

After one

hour, the drug concentration was reduced to
1.6 x 10

M.

At intervals,

the ability of

drug and control cells to incorporate ^H-lleucine (2^c/ml) was determined.

The cells

were incubated for 20 minutes with the radio¬
compound.
indicated.

The standard error of the mean is

100

-

-
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CHART 26.

Incorporation of

K~ 1-Leucine Into Cells Treated

with Arabinosylcytosine in S.

- - Synchronously

growing cells (5.23 x 10^) were incubated with
arabinosylcytosine (1 x 10“^ M) during S for one
hour.

After one hour, the drug concentration

was reduced to 1.6 x lO”'7 M.

At intervals,

the

ability of drug-treated and control cells to inO

corporate °H-l-leucine (2/^c/ml) was determined.
The cells were incubated for 20 minutes with the
radiocompound.
is indicated.

The standard error of the mean
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TABLE 24

PROTEIN SYNTHESIS BY ARABINOSYLCYTOSINE
TREATED CELLS3
■

1
Sample

n

"

cell
number
X 106

control

1 1 1 1 .." ""
mean cell
volume, cu¬
bic microns

'

-

total protein
per culture
mg

~"n
protein
per 10^
cells, mg

6.47

1250

1.26

195

G1

3.07

2536

1.22

397

si

3.12

2536

1.18

379

aMitotic cells (2.5 x 10^) were innoculated, and
during their subsequent cycle were incubated for one
hour with arabinosylcytosine (lx 10"^ M) in G1 or S^.
After one hour, the drug concentration was reduced to
1.6 x 10

M.

Twenty-one hours after the cultures were

returned to 37° C, the cells were collected and the
number of cells, cell volume, and cellular protein were
determined.
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incubated with the drug at 1 x 10
dine at 1 x 10“^ M, do grow well.

-7

M, and deoxycytiThere is no signifio

cant alteration, however, in their incorporation of JIIuridine (Chart 27) and ^H-1-leucine (Chart 28).

*

o

CHART 27. Incorporation of JH-Uridine into Cells Rescued
After Treatroent with Arabinosv1cytosine during
Gl.

-- Synchronously growing cells (4.64 x 10^)

were treated with arabinosylcytosine (lx 10*'1 M)
for one hour during Gl.

After the drug concentre-

tion had been reduced to 1.6 x 10
/

dine (1 x 10

-A

-7

M, deoxycyti-

.

M) was added to all cultures.

At

intervals the ability of rescued and control cul¬
tures to incorporate ^H-uridine (3c/mmole, 2.5 x
10“ 7 M) was determined.

The cells were incubated

for ten minutes with the radiocompound.
ard error of the mean is indicated.

The stand¬

The outgrowth

of rescued cultures was 787, that of the controls
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CHART 28. Incorporation of ^ll-1-Leucine into Rescued Cells
Treated with Arablnosylcytosine in Gl.
chronously growing cells (5.38 x 10

Syn-

) were incu¬

bated for one hour with arabinosylcytosine
(1 x 10"*^ M) during Gl.

After-the drug concentra¬

tion had been reduced to 1.6 x 10"^ M deoxycytidine (1 x 10“^ M) was added to all cultures.

At

intervals, the ability of rescued and control
o

cells to incorporate
determined.

H-l-leucine (2y*-<c/ml) was

The cells were incubated for 20 min¬

utes with the radiocompound.
of the mean is indicated.

The standard error

4

IV.

DISCUSSION

During the past seven years there have been numerous
attempts to define the mechanism of action cf arabinosylcytosine.

Hopefully,

an understending of how this agent

works by leading to its employment in the treatment of
human neoplastic disease in a more

"rational" manner,

would enhance its value as a cancer chemotherapeutic agent.
Such research might also lead to a more intimate knowledge,
of cellular metabolism in normal and neoplastic cells.
At the present time there are a few well accepted
"actions" of the drug and several biochemical mechanisms
which explain in part the observed effects of the drug.
There seems to be little doubt that arabinosylcytosine in
appropriate doses kills organisms ranging in complexity
from viruses to mammals

(6-16,

18-30).

The most striking

disturbance of cellular metabolism caused by ara-C is the
cessation of DNA synthesis,
administered to cells
structural analog

soon after the drug has been

(31-37).

Arabinosylcytosine is a

of cytidine and deoxycytidine,

com¬

pounds which are unreplaceable constituents of nucleic
acids.

The reversal of the drug's-cytotoxicity by deo¬

xycytidine under certain conditions

(see I.C.7.)

supports
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mechanisms implying an interference of nucleic acid
synthesis.

There have been no reports of an arabino-

sylcytosine interference with the overall synthesis of
RNA and protein.

The drug's interference with the syn¬

thesis of histones and histone-messenger RNA appears
to be related primarily to its effect on DNA synthesis
(44,45).

The strongest evidence for the synthesis of

fully functional RNA and protein in the presence of arabinosylcytosine is the observation that the drug does
not suppress the reproduction of RNA viruses.
An explanation of how arabinosylcytosine inter¬
feres with DNA synthesis has been proposed by several
investigators.

In arabinosylcytosine treated cells,

there is a marked diminution in the reduction of CDP to
dCDP (18).

A decrease in dCTP available for DNA syn¬

thesis could depress DNA synthesis.

Study of the drug's

effect on a reductase enzyme system in whole cell ex¬
tracts tends to support the above observation (53).

On

the other hand ara-C, ara-CDP, and ara-CTP seem to have
little effect on the functioning of a partially purified
reductase enzyme system (54).

It has also been found that

the pool of deoxycytidine in arabinosylcytosine treated
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cells is sufficient to carry on DNA synthesis (52).
These findings imply that the primary block in nucleic
acid synthesis is at a further step in the biosynthetic
sequence.
Arabinosylcytosine is incorporated in small amounts
into DNA by whole cells (29, 34, 42),

Such an incorpor¬

ation by destroying the DNA molecule's ability to func¬
tion as a template could explain the interruption of
DNA synthesis in arabinosylcytosine treated cells.

It

has been found, however, that arabinosylcytosine treated
cells can resume DNA synthesis after the drug is removed
(37, 52).

A temporary or reversible interruption of DNA

synthesis is not sufficient to explain entirely the drug's
cytotoxicity.

In partially purified mammalian enzyme

systems, it is not clear whether the drug is incorporated
into DNA (40, 41a).
The reversal of arabinosylcytosine's toxicity by
deoxycytidine can be explained in several ways.

In

partially purified enzyme systems or whole cell extracts,
arabinosylcytosine, probably as ara-CTP, since this is one
active form of the drug, appears to be a competitive in¬
hibitor of DNA polymerase (38-40).

The competition is
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specific for dCTP.
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Deoxycytidine also decreases the

amount of arabinosycytosine accumulated by cells,
presumably by competing with the drug for deoxycytidine
kinase

(29,

49).

By substrate competition deoxycyti¬

dine prevents the phosphorylation of the drug which
has a relatively low affinity for the enzyme

(51).

Cells treated with arabinosylcytosine undergo
unbalanced growth,

a process indistinguishable from

that produced by a variety of other inhibitors of DNA
synthesis

(61-68).

sine treated cells,

Unbalanced growth in arabinosylcyto¬
like that in cells inhibited by

other DNA antimetabolites,

is not immediately lethal

to cells, but becomes progressively so over a period
of time.
as

At the present time there is ne explanation

to how the process kills cells.

anism is,

Whatever the mech¬

it appears to operate in all cells treated

with inhibitors of DNA synthesis.
Arabinosylcytosine causes a variety of chromosomal
abnormalities,

any one of which could be lethal (30,

81,

Since the only cells which die are those which undergo
unbalanced growth (and do not synthesize DNA),

the rela¬

tionship between chromosomal damage and cytotoxicity has

83).

-4*

41
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no t been veil defined.
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Arabinosylc.ytosine treated

cells which pass through mitosis even though they
may have chromosomal abnormalities apparently are
quite capable of continued reproduction.
The above observations explain arabinosylcytosine's cytotoxic effect on cells as the result of an
inhibit ion of DNA synthesis

leading to unbalanced

growth and eventual cell death.

There may be several

mechanisms by which DNA synthesis is inhibited.
inhibit ion, however,

The

is competitive and reversible.

Because logarithmically growing cultures are com¬
posed of cells in all stages of the cell cycle,

the

analysis of a drug's effect in such a mixed population
of cells is inherently difficult.
ously growing populations of cells,
simplified.

By using synchron¬
the analysis is

The method used in this study gives reason¬

able synchronized populations which can be followed
through M, Gl,

and S

(110).

Since the cell cycle of

Don-C cells is 11 hours and the various stages are
shorter,

it was decided to treat cells with the drug

for one hour.

This length of treatment was felt to

approximate more closely the situation in animal studies,
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in which the drag, when given intravenously, is rapidly
cleared from the blood stream (111).
With short periods of treatment, it was found that
the drug concentration to be cytotoxic had to be raised
from a dose (lx 10”^ M) which when present continuously
would effectively prevent cell growth, to much higher
concentrations (lx 10~^ M).

At the lower concentration

(1 x 10 ^ M), arabinosylcytosine effectively inhibits
DNA synthesis.

This inhibition can be reversed, however,

by reducing the drug concentration to 1 x 10~^ M, a
level which does not prevent cell growth, or by adding
deoxycytidine (lx 10”^ M).

Deoxycytidine also reduces

the intracellular accumulation of the drug by a factor of
twenty.
There is a marked difference in the response of
cells at different stages of the cell cycle to treat¬
ment with higher drug concentrations (lx 10"^ M).

Cells

in G1 were not killed when treated with arabinosylcytosine at levels as high as 1 x 10

-3

M.

On the other hand,

cells in S, when treated with arabinosylcytosine at
1 x 10”^ M for one hour, were irreversibly blocked as far
as DNA synthesis was concerned, and eventually died.

111-
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Deoxycytidine (lx 10”^ M) could not reverse the cyto¬
toxic effect of the drug in these cells.

Unbalanced

growth occurs in all cells treated with arabinosylcytosine.
Arabinosylcytosine appears to kill cells in two
ways.

At relatively low drug concentrations

(10

M),

the drug inhibits DNA synthesis and induces unbalanced
growth.

If the inhibition is maintained,

eventually die.
however,

the cells

The process is not immediately lethal,

and can be reversed by removing the drug or by

adding deoxycytidine

(10~^ M) .

An inhibition of DNA

synthesis caused by a high extracellular concentration
of arabinosylcytosine (10 ^ M) can also be reversed if
deoxycytidine is given concommitantly with the drug.
Under these conditions,

the intracellular concentration

of arabinosylcytosine is reduced.

This reversible inhi¬

bition caused by arabinosylcytosine appears to be
ized at the polymerization step itself.

local¬

All components

necessary for DNA polymerization are present in arabino¬
sylcytosine treated S cells,

as DNA synthesis takes

place before drug treatment, and if deoxycytidine is
given,

after drug treatment.

consistant with,

These observations are

and can be explained by a competitive

inhibition of DNA polymerase by arabinosylcytosine.

Such
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an inhibition has been shown in vitro (38-40).
When cells in S are treated with arabinosylcytosine at high levels

(10~^ M),

there is an inhibition

of DNA synthesis which cannot be reversed.

A mechan¬

ism producing an outright kill - cytocidal rather than
•"cytostatic" - appears to be operative.
like G1 cells,

Since S cells,

lose arabinosylcytosine after treatment,

and accumulate and phosphorylate exogenous deoxycytidine,

it would seem that these cells after a sufficient

interval would attain a situation (ara-C/dCyd)
DNA synthesis could resume.

in which

The irreversible inhibi¬

tion caused by arabinosylcytosine appears to be local¬
ized at the polymerization step itself.

All components

necessary for DNA polymerization are present in arabino¬
sylcytosine treated S cells,
place before drug treatment.

as DNA synthesis takes
An irreversible or non¬

competitive inhibition of DNA polymerase has not been
shown in vitro.
albeit small,

could cause an irreversible blockage of

DNA synthesis.
strated

(29,

Incorporation of the drug into DNA,

34,

Such an incorporation has been demon¬
42).

The inhibition of the reduction of CDP to dCDP by
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a ribonucleotide reductase may be an indirect,

rather

than a direct effect of arabinosylcytosine treatment.
The drug,

by inhibiting DNA synthesis in intact cells and

whole cell extracts,

may lead to an increase in the

concentration of deoxynucleotide triphosphates suffi¬
cient to inhibit the reduction of CDP to dC-DP.
purified reductase enzyme system,
little effect on the enzyme

In a

the drug would have

(54).

The observations reported here do not rule out
the possibility that arabinosylcytosine may have other
biochemical actions.

Its effect on RNA and protein

synthesis appears to be limited.
treated cells,

the most sensitive biochemical step,

side of DNA synthesis,
RNA

(44,

45).

In arabinosylcytosine
out¬

may be an alteration in messenger

At the present time the best test of a

messenger's functional integrety is the replication of
RNA viruses which must use their original genome as a
template to replicate more RNA and also to direct the syn¬
thesis of viral proteins.

Arabinosylcytosine has no In¬

hibitory effect on RNA viruses.
The treatment of neoplasms with arabinosylcytosine
could take two forms,

A continuous infusion of the drug

would lead to a sustained state of unbalanced growth
and eventual cell death.

The concentration of the

drug required would be whatever is sufficient to
induce unbalanced growth.

The length of treatment

would have to be relatively long,

i.e.

until the pro¬

cess of unbalanced growth were irreversible.
other hand,

On the

cells could be killed by relatively short

treatments with high concentrations of arabinosylcytosine.

Since only S cells are killed,

treatment would

have to be repeated at a time when the cells, which
were in G2, M,

and G1 during the previous treatment,

had passed through into S.
The present study demonstrates the importance of
considering not only the relationship between drug con¬
centration and length of treatment, and cytotoxicity
in the evaluation of antimetabolities, but also the stage
of the cell cycle during which treatment takes place.
With arabinosylcytosine an immediate kill takes place
only when cells in the S phase are exposed to high con¬
centrations of the drug.

.

115-

-

V.

REFERENCES

1.

BERGMANN, W., and FEENEY, R. J
1950.
The
isolation of a new thymine pentoside from
sponges.
J. Am. Chem. Soc., 72:2809-2810.

2.

BERGMANN, W., and FEENEY, R. J.
1951.
Con¬
tributions to the study of marine sponges.
J. Org. Chem., 16:981-987.

3.

BERGMANN, W., and BURKE, D. C.
1955.
Contri¬
butions to the study of marine products.
J. Org. Chem., 20:1501.

4.

WARWICK, E. R.,
W. K., and DEKKER, C. A.
1959.
Cyclization during the phosphoryla¬
tion of uridine and cytidine by polyphospheric acid- route to 0^, 22-cyclonucleo¬
sides.
Pro. Chem. Soc. p. 84.

5.

HUNTER, J
H.
3,116,282.

6.

RENTS, H. E., and JOHNSON, H. G. 1962.
Inhi¬
bition of plaque formation of vaccinia
virus by cytosine arabinoside hydrochloride.
Bact. Proc., 45:140.

7.

BUTHALA, D. A.
1964.
antiviral agents.
115:69-77.

8.

KIT, S., DUBBS, DELROSE, FREARSON, P. M., and
MELNICK, J. L. 1964.
Enzyme induction in
SV40 infected Green Monkey kidney cultures.
Virology, 1:69-83.

9.

BUTEL, J.
S., and RAPP. F.
1965.
The effect
of ArabinofuranosyIcytosine on the growth
cycle of Simian Virus 40.
Virology,
27:490-495.

Dec.

30,

1963.

U.

S.

Patent

Cell culture studies on
Proc. Soc. Exp. Biol. Med.,

■V

116-

-

10.

HOLLINSHEAD, A. C., and HUEBNER, R. J.
1966.
Adenovirus 12 virion-free "X" antigen from
infected cells inhibited with Cytosine Arabinoside.
Nature, 210: 1381-1383.

11.

UNDERWOOD, G. E.
1962.
Activity of 1-^-D-arabinofuranosylcytosine hydrochloride against
Herpes simplex keratitis.
Proc. Soc. Exp.
Biol. Med., 11:660-664.

12.

KAUFMAN, H. E., and MALONEY, E. D. 1963.
IDU
and Cytosine Arabinoside in experimental
Herpetic keratitis.
Arch. Ophthalmol.,
69:626-629.

13.

ELLIOTT, G. A., and SCHUT, A. L. 1965.
Studies
with Cytarabine HC1 (CA).
Amer. J. Ophtal.,
60:1974-1082.

14.

GORDON, D., and ADVOCATE, S. 1965.
Vaccinial
Rlepharokoratitis treated with Cytosine
Arabinoside.
Amer. J. Ophthal, 59:480-483.

15.

SLECHTA, L.
1961.
Effect of arabinonucleosides
on growth and metabolism of EL coli. Fed.
Proc., 20:357.

16.

PITTILLO, R. F., and HUNT, D. E.
1967.
Cytosine
arabinoside sensitivity in actinobolin resist¬
ant Streptococcus faecalis:
The basis of a
utilitarian microbiological assay.
Proc. Soc.
Exp. Biol. Med., 124:636-640.

17.

PIZER, L. I., and COHEN, S. S.
1960.
Metabolism
of pyrimidine arabinonucleosides and cyclonu¬
cleosides in Eseherichia coli.
J. Biol. Chem.,
235:2387-2342'.

18.

CHU, M. Y., and FISCHER, G. A. 1962.
A proposed
mechanism of action of 1-/^ -D-arabinofurariosylcytosine as an inhibitor of the growth of leu¬
kemic cells.
Biochem. Pharmacol., 11:423-430.

117-

-

19.

BURCHENAL, J. H., ADAMS, H. H., NEWELL, N. S.,
and FOX, J. J.
1966.
Comparative activity
of
-D-arabinofuranosyl-5-fluorocytosine
and related compounds against transplanted
mouse leukemias in vivo and in vitro.
Can¬
cer Res., 26:370-373.

20.

SMITH, C. G., BUSKIRK, H. H., and LUMMIS, W. L,
1965.
Effects of arabinofuranosyluracil on
the cytotoxicity of arabinofuranosylcytosine
in PPLO contaminated cell cultures.
Proc.
Am. Ass. Can, Res., 6:60.

21.

EVANS, J. S., MUSSER, E. A., MENGEL, G. D.,
FORSBLAD, K. R., and HUNTER, J. H.
1961.
Antitumor activity of
-D-arabinofuranosylcytosine hydrochloride (26335).
Proc. Soc. Exp.
Biol. Med., 106:350-353.

22.

EVANS, J. S., MUSSER, E. A., BOSTWICK, L., and
MENGEL, G. D.
1964.
The effect of 1-/7 -Darabinofuranosylcytosine hydrochloride on
murine neoplasms.
Cancer Res., 24:1285-1993.

23.

WODINSKY, I., and KENSLER, C. J.
1965.
Activity
of Cytosine Arabinoside (NSC-63878) in a spec¬
trum of rodent tumors.
Cancer Chemother.
Rep., 47:65-68.

24.

KIMBALL, A. P., LEPAGE, G. A., and ALLINSON, P. S.
1967.
Further studies on the metabolic effects
of 9-/^ -D-arabinofuranosyl-9-H-purine-6-thiol.
Cancer Res., 27:106-116.

25.

SMITH, C.
G.
1966.
Biochemical and biological
studies with arabinofuranosylcytosine.
Proc.
Ill Int. Pharm. Cong, in press.

26.

TALLEY, R. W., and VAITKEVICIOUS, V. K. 1963.
Megaloblastosis produced by a cytosine anta¬
gonist.
I-/5 -D-arabinofuranosylcytosine.
Blood, 21:352-262.

118-

-

27.

HOWARD, J. P., CEVIK, N. , and MURPHY, M. L.
1966.
Cytosine Arabinoside (NSC 63873)
in acute leukemia in children.
Cancer
Chemother., Rep., 50:287-291.

28.

TALLEY, R. W. , O’BRYAN, R. M. , TUCKER, W. G.,
and LOO, R. V.
1967.
Clinical pharma¬
cology and human antitumor activity of
Cytosine Arabinoside.
Cancer 809-816.

29.

CREASEY, W. A., DECONTI, R. C., and KAPLAN,
S. R. 1968.
Biochemical studies with
1 -fi -D -arabinofuranosylcytosine in human
leukemic leukocytes and normal bone marrow
cells.
Cancer Res., 28:1074-1081.

30.

HENDERSON, E. S., and BURKE, P. J. 1965.
Clinical experience with Cytosine Ara¬
binoside.
Proc. Am. Ass. Can. Res., 6:26.

31.

RAPP, F., BUTHEL, J. S., FELDMAN, L. A.,
KITAHARA, T., and MELNICK, J. L. 1965.
Differential effects of inhibitors on the
steps leading to the formation of SV40
tumor and virus antigens. J. Expt. Med.,
121:935-944.

32. LEVITT, J., and BECKER, Y.
1967.
The effect
of Cytosine Arabinoside on the replication
of Herpes simplex virus.
Virology, 31:12.9134.
33. BREWEN, J. G.
1965.
Induction of chromatid
lesions by Cytosine Arabinoside in postDNA synthetic human leukocytes.
Cytogenetics,
4:28-36.
34. SILAG1, S.
1965.
Metabolism of 1-/5-D-arabinofuranosylcytosine in L cells.
Cancer Res.,
25:1446-1453.
35. KARON, M. , HENRY, P., WEISSMAN, 5., and MEYER, c
1966.
The effect of 1--D-arabinofuranosylcyto
sine on macrornolecular synthesis in KB spinner
cultures.
Cancer Res..s 26:166-1.

119-

-

36.

CREASEY, W. A., PAPAC, R. J. , MARKIW, M. E. ,
and WELCH, A. D. 1966.
Biochemical and
Pha rrnacological studies with 1-P -D-arabinofuranosylcytosine in man.
Biochem.
Pharm., 13:1417-1428.

37.

DOERING, A., KELLER, J., and COHEN, S. S.
1966.
Some effects of D-arabinosyl
nucleosides on polymer synthesis in
mouse fibroblasts.
Cancer Res., 26:24442450.

38.

BEN-PORAT, T. , BROWN, M. , and KAPLAN, AL. S.
1968.
Effect of 1-/3 -D~arabinofuranosylcytosine on DNA synthesis.
Mol. Phar¬
macol., 4:139-146.

39.

KIMBALL, A. P., and WILSON, M. J. 1968.
In¬
hibition of DNA polymerase by /3-D-Arabinosylcytosine and reversal of inhibition by
deoxycytidine-51-triphosphate.
Proc = Soc.
Exp. Biol. Med., 127:429-432.

40.

FURTH, J. J., and COHEN, S. S. 1968.
Inhibi¬
tion of mammalian DNA polymerase by the 5’triphosphate of 1-/9 -D-arabinofuranosylcyto
sine and the 5'-triphosphate of 9-/^-D-arabinofuranosyladenine.
Cancer Res., 28:
2061-2067.

41.

CARDEILHAC, P. T., and COHEN, S. S. 1964.
Sone metabolic properties of nucleotides
of 1-/3-D-arabinofuranosylcytosine.
Cancer
Res., 24:1595-1602.

41a.

42.

MOMPARLER, R. L.
1969.
Effect of cytosine
arabinoside 5 *-triphosphate on mammalian
DNA polymerase.
Biochem. Biophys. Res.
Commun., 34:465-471.
CHU, M. Y. and FISCHER, G. A. 1968.
The incor
poration of ^H-Cytosine Arabinoside and its
effect on murine leukemic cells.
Biochem.
Pharmacol.
17:753-767.

120-

-

43.

YOUNG, C. W., and HODAS, S. 1965,
Acute
effects of cytotoxic compounds on the
incorporation of precursors into DNA,
RNA, and protein of KeLa monolayers.
Biochera. Pharmacol., 14:205-214.

44.

BORUN, T. W., SCHARFF, M. D., and ROBBINS,
E. 1967.
Rapidly labeled, polyribosomeassociated RNA having the properties of
histone messenger.
Proc. Natl. Acad.
Sci. U, S., 58:1977-1983.

45.

ROBBINS, E., and BORUN, T. W. 1967.
The
cytoplasmic synthesis of histones in
HeLa cells and its temporal relation¬
ship to DNA replication.
Proc. Natl.
Acad. Sci. U. S., 57:409-416.

46.

KESSEL, D., HALL, T. C., and WODINSKY, I.
1967.
Transport and phosphorylation
as factors in the antitumor action of
cytosine arabinoside.
Science, 156:
1240-1241.

47.

SCHRECKER, A. W., and URSHEL, M. J. 1968.
Metabolism of 1-/? -D-arabinofuranosylcytosine in leukemia L1210: Studies' with
intact cells.
Cancer Res., 28: 793-801.

48.

JACQUEZ, J. A. 1962.
Transport and enzymatic
splitting of pyrimidine nucleosides in
Ehrlich cells.
Biochem. Biophys. Acta,
61:265-277.

49.

KAPLAN, A. S., BROWN, M., and BEN-PORAT, T.
1968 Effect of 1-/3 -D-arabinofuranosylcytosine on DNA synthesis.
I.
In nor¬
mal rabbit kidney cell culture.
Molecular
Pharmacology, 4:131-138.

50.

CHU, M. Y., and FISCHER, G. A. 1965.
Compara¬
tive studies of leukemic cells sensitive
and resistant Cytosine Arabinoside.
Biochem.
Pharm., 14:333-341.

121-

-

51.

HOMPARLER, R. L., and FISCHER, G. A.
Mammalian deoxynucleoside kinases.
Biol. Chem., 243:4298**4303.

1968.
J.

52.

CHU, M. Y., and FISCHER, G. A. 1968.
Effects
of Cytosine Arabinoside on the cell via¬
bility and uptake of deoxypyrimidine nu¬
cleosides in L5178Y cells.
Biochem. Phar¬
macol. 17:741-751.

53.

KIMBALL A. P., BOWMAN, G., BUSH, P. S.,
HERRIOT, J., and LEPAGE, G. A. 1966.
Inhibitory effects of the arabinosides
of 6-Mercaptopurine and cytosine on
purine and pyrimidine metabolism.
Cancer
Res., 26:1337-1343.

54.

MOORE, E. C., AND COHEN, S. S. 1967.
Effects
of arabinonucleotides on ribonucleotide
reduction by an enzyme system from rat
tumor.
J. Biol. Chem., 242:2116-2118.

55.

COHEN, S. S., and BARNER, H. D.
1954.
Studies on unbalanced growth in Escher¬
ichia coli.
40:835-893.

Proc.

Natl. Acad.

Sci. U.

S.,

56.

ROLFE, R. 1967.
On the mechanism of thymine¬
less d eath in B^_ subtilis.
Proc. Natl.
Acad. Sci. U. S., 57:114-121.

57.

SICARD, N., and DEVORET, R.
1962.
Effets
de la carence en thymine sur des sonches
d'Escherichia ccli lysosgenes K12T” et
colicinogene 15 T“.
Compt. Rend., 255:
1417-1419.

58.

GOLDTHWAITE, D., and JACOB, F. 1964.
Sur le
mecanisme de 1'induction du diveloppement
du prophage chez les bacteries lysogenes.
Comp. Rend., 259:661-664.

59.

ENDO, H. AYABE, K. , AMAKO, K., AND TAKEYA, K.
1965.
Inducible phage of Escherichia coli
15.
Virology, 25:469-471.

60.

ATKINSON, C., and STACEY, K. A. 1968.
Thymineless death induced by cytosine arabinoside.
Biochem. Biophys. Acta, 166:
705-707.

61.

RUECKERT, R. R., and MUELLER, G. C. 1960.
Studies on unbalanced growth in tissue
culture.
Cancer res., 20:1584-15.

62.

EIDIN0FF, M. L., and RICH, M. A. 1959.
Growth inhibition of a human tumor cell
strain by 5-fluoro-2’-deoxyuridine.
Time parameters for subsequent reversal
by thymidine.
Cancer Res., 19:521-524.

63.

COHEN, L. S., and STUDZINSKI, G. P. 1967.
Correlation between cell enlargement
and nucleic acid and protein content of
HeLa cells in unblanaced growth produced
by inhibitors of DNA synthesis.
J. Cell
Physiol., 69:331-339.

64.

KIM, J. H., KIM, S. H., and EIDINOFF, M. L.
1965.
Cell viability and nucleic acid
metabolism after exposure of HeLa cells
to excess thymidine and deoxyadenosine.
Biochem Pharmacol., 14:428-437.

65.

LAMBERT, W., and STUDZINSKI, G.
1967.
Re¬
covery from prolonged unbalanced growth
induced in HeLa cells by high concentra¬
tions of thymidine.
Cancer Res., 27:
2364-2369.

66.

YOUNG, C. W., and HODES, S. 1964.
Hydroxyurea
Inhibitory effect on DNA metabolism.
Sci¬
ence, 146:1172-1174.

.

67

KIM J. H., and EIDINOFF, M. L. 1965. Action
of 1-/3 -D-arabinofuranosylcytosine on the
nucleic acid metabolism and viability of
HeLa cells.
Cancer Res., 25:698-702.

-123-

68.

KIT, S., DETORRES, R. A., and DUBBS, D. R.
1966.
Arabinofuranosylcytosine induced
stimulation of thymidine kinase and deoxycytidylic deaminase activities of mam¬
malian cultures.
Cancer Res., 26:1839-18.

69.

KIM, J. H., PEREZ, A. G., and DJ0RDJEV1C, B.
1968.
Studies on unbalanced growth in
synchronized HeLa cells.
Cancer Res.,
28:2443-2447.

70.

ANDERSON, E. C., PETERSEN, D. F., and TOBEY,
R. A.
1967.
Biochemical balance and
synchronized cell cultures.
Nature, 215:
1033-1084.

71.

LITTLEFIELD, J. W., McGOVERN, A. P., and
MARGESON, K. B. 1963.
Changes in the dis¬
tribution of polymerase activity during
DMA synthesis in mouse fibroblasts.
Proc.
Natl. Acad. Sci. U. S., 49:102-107.

72.

ADAMS, R. L. P., ABRAMS, R., and LIEBERMAN, I.
1965.
Rise in deoxyribonucleic acid poly¬
merase activity in the absence of deoxyri¬
bonucleic acid synthesis in cultured kidney
cells.
Nature, 206:512-513.

73.

ADAMS, R. L. P., ABRAMS, R. , and LIEBERMAN, I.
1966.
Deoxycytidvlate synthesis and entry
into the period of deoxyribonucleic acid
replication in rabbit kidney cells.- J. Biol.
Chern. 241:903-905.

74.

STUDZINSKI, G. P., COHEN, L. S., ROSEMAN, J.,
and SCHWEITZER, J. L. 1966.
Elevation of
decxynuclease activity in HeLa cells treated
with selective inhibitors of DNA synthesis,
Biochem. Biophys. Res. Com., 25:313-319.

75.

KIT, S., DETORRES, R. A., and DUBBS, D. R. 1967.
Deoxycytidylate deaminase activity of Simian
virus 40 infected cell cultures.
Cancer Res.,
27:1907-1914.

-124-

76.

RAPP, F., and MELNICK, J. L. 1966.
The
footprints of tumor viruses.
Sci. Am.,
214:34-41.

77.

HIRSCHMAN, S. Z. 1969.
Effect of cytosine
arabinoside on the replication of the
moloney sarcoma virus in 3T3 cell cul¬
tures.
Proc. Am. Ass. Can. Res., 10:38.

78.

EVANS, J. S., and MENGEL, G. D. 1964.
The
reversal of Cytosine Arabinoside activity
in vivo by deoxycytidine.
Biochem. Phar¬
macol., 13:989-994.

79.

PAPAC, R. J., CALABRESI, P., HOLLINGSWORTH,
J. W., and WELCH, A. D. 1965.
Effects
of 1-/6 -D-arabinofuranosylcytosine hydro¬
chloride on regenerating bone marrow.
Cancer Res., 25:1459-1462.

80.

KIHLMAN, B. A., NICHOLS, W. W., and LEVAN, A.
1963.
The effect of deoxyadenosine and Cy¬
tosine Arabinoside on the chromosomes of
human leukocytes _in vitro.
Hereditas, 50:
139-143.

81.

BREWEN, J. G., and CHRISTIE, N. T. 1967.
Studies on the induction of chromosomal
aberrations in human leukocytes by Cyto¬
sine Arabinoside.
Expt. Cell Res., 46:
276-291.

82.

MOMPARLER, R. L., Chu, M. Y., and FISCHER, G. A.
1968.
Studies on a new mechanism of resist¬
ance of L1578Y murine leukemia cells to cyto¬
sine arabinoside.
Biochem. Biophys. Acta,
161:481-493.

83.

NICHOLS, W. W., and HENEEN, W. K.
196.
Chromosomal effects of arabinosylcytosine
in a human deploid cell strain.
Hereditas,
52:402-410.

-125-

84.

HOWARD, A., and PELC, S. R. 1953.
Synthesis
of desoxyribonucleic acid in normal and
irradiated cells and its relation to
chromosome breakage.
Heredity (Suppl),
6:261-273.

85.

LAJTHA, L. G., OLIVER, R., and ELLIS, F.
1954. Incorporation of 32p and adenine
14q into DNA by human bone marrow cells
in vitro.
Brit. J. Cancer, 8:367-379.

86.

PUCK, T. T., and STEFFEN, J. 1963.
Life
Cyc le analysis of mammalian cells.
Biophys. J., 3: 379-397.

87.

ROBBINS, E., JENTZSCH, G., and MICALI, A.
1968.
The centriole cycle in synchronized
HeLa cells.
J. Cell Biol., 329-340.

88.

KLEVECZ, R. R., and STUBBLEFIELD, E. 1967.
RNA synthesis in relation to DNA replicati on in synchronized Chinese hamster cell
cultures.
J. Exp. Zool., 165:259-268.

89.

FUJIWARA, Y. 1967.
Role of RNA synthesis in
DNA replication of synchronized populations
of cultured mammalian cells.
J. Cell Phy¬
siology, 70:291-300.

90.

PFEIFFER, D.
1968.
RNA synthesis in synchronously
growing populations of HeLa S3 cells.
Rate
of synthesis of individual RNA fractions.
J.
Cell Physiology, 71:95-104.

91.

ENGER, M., TOBEY, R., and SAPONARA, A.
1968.
RNA synthesis in Chinese hamster cells:
Differential synthetic rate for ribosomal
RNA in early and late interphase.
J. Cell
Biol., 36: 583-595.

92.

STUBBLEFIELD, E., and MURPHREE, S.
1967.
Syn¬
chronized mammalian cell cultures.
II.
Thymidine kinase activity in colcemid syn¬
chronized fibroblasts.
Exp. Cell Res.,
48:652-656.

t

126-

-

93.

ICAJIWARA, K. , and MUELLER, G. C. 1964.
Mole¬
cular events in the reproduction of animal
cells.
Bicchem. Biophys. Acta, 91: 846-493.

94.

GOLD, M., and HELLEINER, C. W.

95.

FURLONG, N. B., NOVAK, B., and STUBBLEFIELD, E.
1969. DNA polymerase activities in nuclear
and cytoplasmic extracts prepared from syn¬
chronized cells.
Proc. Am. Ass. Can. Res.,
10:27.

96.

BRENT, T. P., BUTLER, J. A. V., and CARTHORN,
A. R. 1965.
Variation in phosphokinase
activities during the cell cycle in syn¬
chronous populations of HeLa cells.
Na¬
ture, 207:176-177.

97.

HOOPER, G.
1967.
Thymidylate synthetase in
mammalian cells jin vitro.
J. Cell Biol.,
35:59A.

1964.
Deoxyri¬
bonucleic acid polymerase in L cells.
I.
Properties of the enzyme and its activity
in synchronized cell cultures.
Biochem.
Biophys, Acta, 80:193-203.

98.

KELEVECZ, R. R., and RUDDLE, F. H.
1968.
Cyclic changes in synchronized mammalian
cell cultures.
Science, 159:634-636.

99.

STUBBLEFIELD, E., in R. J. C. HARRIS (ed).
1964.
Cytogenetics of Cells in Culture,
p. 233.
New York:
Academic Press.

100.

PEIFFER, S. E., and TOLMACH, L. J. 1967.
Se¬
lecting synchronous populations of mammal¬
ian cells.
Nature, 213:139-142.

101.

GALAVAZI, G., SCHENK, H., and BOOTSMA, D.
1966.
Synchronization of mammalian cells
in vitro by inhibition of DM synthesis.
Expt. Cell Res., 41:428-437.

.

127-

-

102.

TILL, J. E. , WHITMORE, G. F., and GULYAS, S.
1963.
Deoxyribonucleic acid synthesis in
individual L strain mouse cells.
Biochem.
Biophys. Acta, 72:277-289.

103.

MORRIS, N. R., CRAMER, J. W., and RENO, D.
1967.
A simple method for concentration
of cells in the DNA synthetic period of
the mitotic cycle.
Exp. Cell Res., 48:
216-218.

104.

SINCLAIR, R., and BISHOP, K. H. L.

105.

TERASIMA, T., and TOLMACH, L. J. 1965.
Growth
and nucleic acid synthesis in synchronously
dividing populations of HeLa cells.
Exp.
Cell Res., 30:344-362.

106.

1965.
Syn¬
chronous culture of strain L mouse cells.
Nature, 205:1272-1273.

KLEINFELD, R. C., and SISKEN, J.E. 1966.
Mor¬
phological and kinetic aspects of mitotic
arrest by and recovery from colcemid.
J.
Cell Biol., 31: 369-379.

107.

TAYLOR, E. W. 1965.
The Mechanism of colchi¬
cine inhibition of mitosis.
I. Kinetics
of inhibition and the binding of ^{--col¬
chicine,
J. Cell Biol., 25:145-160.

108.

BORISY, G. G., and TAYLCR, E. W. 1967.
The
mechanism of action of colchicine.
I.
Binding of Colchicine-^H to cellular pro¬
tein.
J. Cell Biol., 34:525-533.

109.

BORISY, G. G., and TAYLOR, E. W. 1967.
The
mechanism of action of Colchicine, II.
Colchicine binding to sea urchin eggs and
the mitotic apparatus.
J. Cell Biol,
34:535-548.

110.

STUBBLEFIELD, E., and KLEVECZ, R. 1965.
Synchronization of Chinese hamster cells
by reversal of Colcemid inhibition.
Exp.
Cell Res., 40:660-664.

128-

-

111.

PAPAC, R. , CREASEY, W. A.‘, CALABRESI, P. ,
and WELCH, A. D. 1965.
Clinical and
pharmacological studies with.
-DarabinofuranosyIcytosine (Cytosine
Arabinoside).
Proc. Amer. Ass. Cancer
Res., 6:50.

112.

CAMIENER, G. W., and SMITH, C. G. 1965.
Studies of the enzymatic deamination
of Cytosine Arabinoside.
Biochemi¬
cal Pharmacology, 14:1405-1416.

113.

SEED, J.
1966.
The synthesis of DNA, RNA
and nuclear protein in normal and tumor
strain cells.
I.
Fresh embryo human
cells.
J. Cell Biol, 28:234-248.

114.

SEED, J.
1966.
The synthesis of DNA,
RNA and nuclear protein in normal and
tumor strain cells.
IV. HeLa tumor.
J. Cell Biol., 28: 263-275.

115.

SKIPPER, K. E., SCHAREL, F. M., and WILCOX,
W. S. 1964.
Experimental evaluation of
potential anticancer agents.
XIII.
On
the criteria and kinetics associated
with "curability" of experimental leukemia.
Ca. Chem. Repts., 35:3-111.

116.

SKIPPER, H. E., SCHABEL, F. M., and WILCOX,
W. S. 1967.
Experimental evaluation of
potential anticancer agents.
Cancer
Chemother.
Rep., 51:125-165.

117. BRUCE, W. R., MEEKER, B. E., and VALERIGTE,
F. A. 1966.
Comparison of the sensitivity
of normal hematopoietic and transplanted
lymphoma colony forming cells to chemother¬
apeutic agents administered in vivo.
J.
Nat. Cancer Inst., 37:233-245.
118. WILKOFF, L. J. , WILCOX, W. S.,- BURDESHAW, J. A.,
Dixon, G. J., and DULMADGE, E. A. 1967.
Effect of antimetabolites on kinetic be¬
havior of proliferating cultured L1210 leu¬
kemia cells.
J. Nat. Cancer Inst., 39:965-975.

129-

-

119.

EAGLE, H.
195$.
Amino acid metabolism in
mammalian cell cultures.
Science, 130:
432-437.

120.

EARLE, V,7. R.
1943.
nancy _in vitro.
4:165-212.'

Production of malig¬
J. Natl. Cancer Inst.,

121. HANKS, J. H., and WALLACE, R. E.
1949.
Relation of oxygen and temperature in
the preservation of tissues by refriger¬
ation.
Proc. Soc. Exp. Biol. Med., 71:
196-200.
122. AMERICAN TYPE CULTURE COLLECTION.
Registry of animal cell lines.
ville, Maryland.

1964.
Rock¬

123. HSU, T. C., and ZENZES, M. T.
1964. Mam¬
malian chromosomes jLn vitro.
J. Natl.
Cancer Inst., 32:857-869.
124.

STUBBLEFIELD, E., KLEVECZ, R., and DEAVAN,
L. 1967.
Synchronized mammalian cell
cultures.
J. Cell Physiol., 69:345-354.

125.

LOVELOCK, J. E., and BISHOP, M. W. H. 1959.
Prevention of freezing damage to living
cells by dimethylsulphoxide.
Nature,
London, 183:1394-1395.

126.

SCHERER, W. F., and HOOGASIAN, A. C. 1954.
Preservation at subzero tempteratures
of mouse fibroblasts (Strain L) and hu¬
man epithelial cells (strain HeLa).
Proc. Soc. Exp. Biol. Med., 87:480-487.

127.

LEVAN, A.
1956.
Chromosomal studies on
some human tumors and tissues of normal
origin grown in vivo and in vitro at
the Sloan Kettering Institute.
Cancer,
9:648-663.

130-

-

128.

MOORHEAD, P. S., NOWELL, P. C., MELLMAN, W. J.,
BATTIPS, D. M., and HUNGERFORD, D. A. 1960.
Chromosome preparations of leukocytes cul¬
tured from human peripheral blood.
Exp.
Cell Res., 20:613-616.

129. MERCHANT, D. J., KAHN, R. H., and MURPHY, W. H.
1964.
Handbook of cell and organ culture.
Minneapolis:
Burgess Publishing Company,
p. 207.
130. ROODYN, D. B., and MANDEL, H. G. 1960.
Mem¬
brane filter fractionation.
Biochem.
Biophys. Acta, 41:80-88.
131. ALPEN, E. L., and MANDEL, H. G. 1960.
A rapid
assay method for tritium in bacterial cells.
Biochem. Biophys. Acta, 43: 317-321.
132.

SCHMIDT, G., and THANNKAUSER, S. J.
1945.
A
method for the determination of desoxyri¬
bonucleic acid, ribonucleic acid, and
phosphoproteins in
animal tissues.
J.
Biol. Chem., 161-83-89.

133.

LOWRY, 0. H., and ROSEBROUGH, N. J.
1951.
Protein measurement with the folin phenol
reagent.
J. Biol. Chem., 193:265-275.

YALE MEDICAL LIBRARY
Manuscript Theses

Unpublished theses submitted for the Master's and Doctor's degrees and
deposited in the Yale Medical Library are to be used only with due regard to the
rights of the authors.

Bibliographical references may be noted, but passages

must not be copied without permission of the authors, and without proper credit
being given in subsequent written or published work.
This thesis by

hd.

^

■> ***•

has been

used by the following persons, whose signatures attest their acceptance of the
above restrictions.

NAME AND ADDRESS

DATE
7!

It
"ft'chard

S./T.

yocs'Otr

Z3 J^n.

73

